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11Introduction
Heart failure is a clinical syndrome characterized by the heart’s inability to meet the 
body’s circulatory demands. Typical symptoms include dyspnea, fatigue, edema and exer-
cise intolerance, accompanied by objective signs of cardiac dysfunction.1 The population 
prevalence of chronic heart failure in The Netherlands was 1% in 2003, and 20-30% in 
people over the age of 70, and continues to rise. Contributing factors include an ageing 
population, improved treatment for chronic heart failure and acute myocardial infarction, 
resulting in better survival. Heart failure has been described as a burgeoning epidemic, 
with Engelfriet et al. predicting a 50% rise in incidence by 2025 in The Netherlands.2
Heart failure may be caused by any condition affecting cardiac function. Persistent pres-
sure or volume overload, myocardial disease or loss of heart muscle. The primary cause 
remains ischemic heart disease. Other common aetiologies include valvular disease, hy-
pertension, myocarditis and cardiomyopathies.
Heart failure is the leading cause of death in the Western world, with a 60% mortal-
ity rate within five years of diagnosis.3 Official statistics frequently underestimate heart 
failure mortality rates, as cause of death is coded by underlying disease (i.e. coronary 
artery disease). Despite the development of new therapies, both short-term and long-
term mortality remains high.4,5 It would appear the ‘benefit ceiling’ for available therapies 
has almost been reached. Therapies not primarily focused on heart failure may reduce 
morbidity and mortality.6,7
In summary, heart failure is generally recognized as a major and escalating health care 
problem in industrialized countries. The number of patients with heart failure is set to 
rise in years to come for several reasons. First, the proportion of elderly patients, which 
have the highest incidence of risk factors such as coronary artery disease and hyperten-
sion, is increasing rapidly. Second, therapeutic developments have improved survival in 
heart disease patients, shifting the burden towards chronic illness.3
Comorbidity in heart failure
In recent decades, growing evidence has accumulated about other diseases and dys-
function of other organs in patients with heart failure. These ‘comorbidities’ frequently 
accompany heart failure and result in worse quality of life and clinical outcome.
The term comorbidity has multiple meanings; first, to indicate a medical condition ex-
isting simultaneously with but independently of another condition in a patient; and sec-
ond, to indicate a medical condition in a patient that causes, is caused by, or is otherwise 
related to another condition in the same patient.8 
Prevalence
Numerous studies have found comorbidities are highly prevalent in patients with heart 
failure, but almost all focus on a single comorbidity – anemia (prevalence of 37%),6 
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cerebral dysfunction (30-60%),9 renal dysfunction (up to 55%),10 liver dysfunction (30-
60%)11 and sleep apnea (60%).12
However, to the best of our knowledge, only two studies have focused on multiple co-
morbidities in patients with heart failure. Examining twenty non-cardiac comorbidities, 
the first found that 96% of all heart failure patients older than 65 years were found to 
have at least one comorbidity, and 40% had 5 or more comorbidities.13 The other study 
focused on an even older population, namely geriatric patients.14
Pathophysiology
The pathophysiologic processes underlying the interaction between heart failure and 
comorbid conditions are complex and remain largely unresolved. High prevalence of 
comorbidities in patients with heart failure suggests a common risk factor or a causal 
relationship. Although a common risk factor causing multiple different comorbidities is 
possible, it is reasonable to believe that heart failure itself might be a cause of multiple 
other comorbidities.15 This is supported by the finding that the prevalence of comorbidi-
ties is associated with the severity of heart failure, measured using the New York Heart 
Association (NYHA) functional classification.16
Several mechanisms in heart failure may contribute to the dysfunction of other or-
gans. First, hemodynamic derangements - the hallmark of the heart failure syndrome 
– may cause dysfunction in other organs.17-21 Second, heart failure causes neurohormonal 
changes which can lead to other organ dysfunction. Heart failure can alter neurohor-
monal status by affecting balance – for instance hormonal, neural, structural, and local 
balance.19 Third, the drugs used to treat heart failure may affect comorbidities (e.g. beta-
blockers affect COPD; ACE inhibitors impact kidney function and anemia). 
Hemodynamic changes are of special interest. As cardiac output, blood is preferentially 
redistributed to certain organs at the expense of others.19 In mild heart failure, the heart’s 
output is still normal at rest, but the output increase normally seen during exercise is 
blunted, leading to a smaller increase in skeletal muscle blood flow. In patients with se-
vere heart failure, cardiac output is already reduced at rest. The heart and brain receive 
normal blood flow at the expense of skeletal muscles and kidneys. As a percentage of 
output, cerebral and coronary blood flow even increase.17,18
Pathophysiologic mechanisms are complex and may differ for individual comorbidities. 
Therefore, comorbidities must be studied separately to identify pathophysiologic associa-
tions.
Of all the comorbidities examined, only two are directly related to an organ - Renal dys-
function and liver dysfunction. Other comorbidities, such as sleep apnea and cognitive 
dysfunction, do not have clear substrates that can be studied easily. Renal dysfunction 
and liver dysfunction are relatively easy to assess and can be studied on a continuous 
scale, rather than dichotomized into dysfunctional or not. 
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Prognosis
Heart failure is the leading cause of death in the Western world and has a 5-year mor-
tality of 60%.3 The presence of comorbidities further impairs survival.6,7,22 Most of the 
research on comorbidities in heart failure was related to a single organ or comorbidity. 
However, when multiple comorbidities are taken into consideration, a strong association 
is observed between non-cardiac comorbidities and adverse clinical outcomes. Hospi-
talization rates increase in the presence of comorbidities. In fact, patients with five or 
more comorbidities account for 81% of all hospital days experienced by all heart failure 
patients.
We are also interested in factors that account for worse prognosis. Although it is difficult 
to study factors that explain the association between comorbidities and prognosis, we 
will focus primarily on hemodynamic factors such as central venous pressure and cardiac 
output.13
Aims
In summary, the prevalence, pathophysiology and prognostic implications of (multiple) 
comorbidities in patients with heart failure remain unresolved. Therefore the main aims 
of the present thesis are: 
1. To assess the prevalence of individual and multiple comorbidities in patients with 
heart failure; 
2. To study whether the prevalence of comorbidities is higher in patients with heart 
failure than in age-matched controls; 
3. To study  pathophysiologic mechanisms connecting heart failure and individual 
comorbidities, as well as determinants of multiple comorbidities; 
4. To establish the prognostic influence of individual and multiple comorbidities.
In chapter 1, we examine multiple comorbidities in a broad spectrum of European pa-
tients with chronic heart failure. We focus on the prevalence, determinants, regional vari-
ation and prognostic implications of multiple comorbidities. In chapters 2-6, we study 
renal and liver dysfunction separately in patients with chronic and acute decompensated 
heart failure.
In chapter 2, we study whether hemodynamic factors could play a pathophysiologi-
cal role in renal dysfunction. We evaluate the association between invasively measured 
hemodynamic parameters, renal dysfunction and prognosis. Chapter 3 focuses on tu-
bular renal function in patients with chronic heart failure. We try to determine whether 
tubular renal function is a better renal parameter for assessing renal function compared 
to two frequently used biomarkers of chronic kidney disease. In contrast with chapters 
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2 and 3, chapter 4 studies renal function in patients with acute decompensated heart 
failure. We examine the pathophysiologic associations and prognostic implications of 
(change in) creatinine in hospitalized patients.
Chapter 5 studies whether hemodynamic factors are of pathophysiological importance 
in liver dysfunction. In addition, associations between abnormal liver function tests and 
prognosis are assessed. In chapter 6 we investigate liver function tests in patients admit-
ted with acute decompensated heart failure. We examine the prognostic value of (change 
in) impaired liver function.
Chapter 7 reviews the prevalence of the most studied organ-related comorbidities in 
heart failure, i.e. renal dysfunction, liver dysfunction, cerebral and cognitive dysfunction, 
anaemia, chronic obstructive pulmonary disease, diabetes mellitus, depression, stroke 
and sleep apnea. We also provide potential explanations for the observed associations be-
tween comorbidities and heart failure, as well as examining their prognostic implications.
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Chapter 1
Comorbidities in heart failure
Vincent M. van Deursen, Renato Urso, Cecile Laroche, 
Kevin Damman, Ulf Dahlström, Luigi Tavazzi, 
Aldo P. Maggioni and Adriaan A. Voors
Comorbidities in patients with heart failure
An analysis of the European Heart Failure pilot survey
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Abstract
Aims
Co-morbidities frequently accompany heart failure (HF), contributing to morbidity, 
impairment of quality of life and  increased mortality. We assessed the prevalence, de-
terminants, regional variation and prognostic implications of co-morbidities in patients 
with chronic HF in Europe.
Methods
3226 European outpatients with chronic HF were included in this analysis of the ESC 
Heart Failure pilot survey. The following co-morbidities were considered: diabetes, hy-
per- and hypothyroidism, stroke, COPD, sleep apnoea, chronic kidney disease (CKD) 
and anaemia. Prognostic implications of co-morbidities where evaluated using popula-
tion attributable risks (PAR), and patients were divided into geographic regions. Clinical 
endpoints were all-cause mortality and HF hospitalization. 
Results
The majority of patients (74%) had a least one co-morbidity, the most prevalent being 
CKD (41%), anaemia (29%) and diabetes (29%). Co-morbidities were independently as-
sociated with higher age (p<0.001), higher NYHA functional class (p<0.001), ischemic 
aetiology of HF (p<0.001), higher heart rate (p=0.011), history of hypertension (p<0.001) 
and atrial fibrillation (p<0.001). Only diabetes, CKD and anaemia were independently 
associated with a higher risk of mortality and/or HF hospitalization. There were marked 
regional differences in prevalence and prognostic implications of co-morbidities. Prog-
nostic implications of co-morbidities (PAR) were: CKD=41%, anaemia=37%, diabe-
tes=14%, COPD=10% and <10% for all other co-morbidities.
Conclusion
In this pilot survey, co-morbidities are prevalent in patients with chronic HF and are 
related to the severity of heart failure. The presence of diabetes, CKD and anaemia was 
independently related to increased mortality and HF hospitalization, with the highest 
population attributable risk for CKD and anaemia
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Introduction
Heart failure is characterized by high morbidity and mortality and a poor quality of life.1 
There is growing awareness that co-morbidities frequently accompany heart failure and 
lead to greater morbidity, a further decrease in quality of life and increased mortality.2-6 
The prevalence of comorbidities is higher in patients with more severe signs of heart fail-
ure. This suggests either common etiological factors - such as age and cardiovascular risk 
factors - or a causal relationship with heart failure. However, determinants of multiple 
co-morbidities remain unknown. 
While numerous studies focus on a single co-morbidity, only few studies have examined 
multiple non-cardiac co-morbidities in patients with heart failure.5,7,8 In a cross-sectional 
study of 122,630 elderly (>65 years) patients with heart failure, the prevalence of co-
morbidities was 96%.5 It was calculated that patients with more than 5 co-morbidities are 
responsible for 81% of all hospital days experienced by all heart failure patients. However, 
regional differences have not been studied and determinants of multiple co-morbidities 
remain unknown.
The present study examines multiple co-morbidities in a broad spectrum of patients 
with chronic heart failure. We focus on the prevalence, determinants, regional varia-
tion and prognostic implications of co-morbidities in a broad spectrum of patients with 
chronic heart failure in Europe. 
Methods
The HF Pilot of the EURObservational Research Programme (EORP) of the European 
Society of Cardiology (ESC) was a prospective, multicentre, observational survey.9 The 
aim was to include a broad spectrum of patients with heart failure from outpatient clinics 
and those admitted to a hospital. Outpatients were diagnosed with chronic heart failure 
according to the clinical judgment of a cardiologist. Admitted patients had pre-existing 
heart failure or new-onset heart failure requiring intravenous therapy. A total of 5,118 
patients were included, 1,892 (37%) in-hospital patients with acute HF and 3,226 (63%) 
outpatients with chronic HF, recruited from 136 cardiology centres in 12 European coun-
tries. These countries were selected on the basis of previous performances in the Euro 
Heart Surveys and geographical distribution. The National Cardiology Societies of each 
country agreed to participate in the program and were asked to select hospitals of differ-
ent levels of complexity. The aim was to involve a broad spectrum of cardiology units. The 
number of participating centers for each country was decided according to the number of 
inhabitants. We used all 3,226 outpatients to obtain a representative chronic heart failure 
population for analysis. 
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Regions
Four geographical regions were defined as follows: Western European countries (Aus-
tria [N=86], France [N=37], Germany [N=138], and The Netherlands [N=76]), East-
ern European countries (Romania [N=120] and Poland [N=243]), Southern European 
countries (Greece [N=115], Italy [N=1387] and Spain [N=532]), and Northern European 
countries (Denmark [N=174], Norway [N=126], and Sweden [N=201]).
Co-morbidities 
Co-morbidities were determined based on the case record form as assessed by the treat-
ing physician. We used all non-cardiac co-morbidities that were assessed in this survey. 
Co-morbidities consisted of diabetes (N=3223), thyroid dysfunction (N=3171), stroke 
(N=3206), chronic obstructive pulmonary disease (COPD, N=3202), sleep apnoea (ei-
ther in medical history or self-reported, N=3197), chronic kidney disease (CKD, defined 
as estimated GFR (eGFR)<60 mL/min/1.73 m2, as well as eGFR on a continuous scale, 
N=2547), and anaemia (using the World Health Organisation definitions of haemoglobin 
<13 g/L (8.1 mmol/L) in men and <12 g/L (7.5 mmol/L) in women, as well as haemoglo-
bin on a continuous scale, N=2522). The number of co-morbidities per patient was also 
assessed. No additional diagnostic tests were performed to determine the presence of 
specific co-morbidities. 
End-points
To study the prognostic association with co-morbidities, all-cause mortality and heart 
failure hospitalization were assessed, with a median follow-up of 364 (335-367) days. 
Statistical analyses 
Data are presented as mean ± standard deviation for continuous variables, and as fre-
quencies and percentages for categorical variables. Categorical variables were compared 
using chi-square tests. Continuous variables were compared using Student’s T-test. 
Cox proportional hazards models were used to estimate hazard ratios for all-cause mor-
tality and heart failure hospitalizations. In multivariate multivariable analyses, the fol-
lowing variables with significant univariable associations with outcome at P≤0.10 were 
included in the model: age, sex, aetiology, hypertension, atrial fibrillation, congestion, 
body surface area, systolic blood pressure and heart rate. 
Population attributable risks (PAR) were computed as confirmatory analyses using the 
package epiR. The estimated attributable fraction in the population was reported with 
95% confidence intervals. The attributable fraction is the proportion of deaths in the pop-
ulation that is attributable to the co-morbidity, as previously used by Yusuf et al.10
A P-value of < 0.05 was considered statistically significant. All tests were two-sided. The 
statistical analyses were performed at the ANMCO Research Center, Florence, Italy, on 
behalf of the European Society of Cardiology, with R (version 2.14.0).
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Age (years) 66±14 63±14 71±11 <0.001
Male gender (%) 2268 (70) 1029 (73) 797 (68) 0.02
Body Mass Index (kg/m2) 28±5 28±5 28±5 0.12
NYHA class <0.001
  I (%) 511 (16) 299 (21) 103 (9)
  II (%) 1797 (56) 828 (59) 600 (52)
  III (%) 854 (26) 277 (20) 431 (37)
  IV (%) 56 (2) 11 (1) 28 (2)
SBP (mmHg) 125±20 125±20 125±21 0.62
Heart rate (b.p.m.) 72±14 72±15 72±13 0.17
Congestion
  Only elevated JVP 242 (8) 90 (6) 105 (9) 0.01
  Only edema 592 (19) 237 (17) 276 (24) <0.001
Ischaemic aetiology (%) 1305 (41) 499 (35) 556 (48) <0.001
ICD/CRT(-D) (%) 745 (23) 110 (8) 122 (10) 0.02
Hypertension (%) 1875 (58) 733 (52) 787 (68) <0.001
History of AF (%) 1289 (40) 486 (34) 586 (50) <0.001
Medication use
    ACE-i/ARBs 2833 (89) 1280 (91) 992 (86) <0.001
    Beta-blockers 2774 (87) 140 (88) 962 (83) <0.001
    Diuretics 2649 (83) 1088 (77) 1041 (90) <0.001
    Aldosterone blockers 1396 (44) 595 (42) 527 (46) 0.10
Comorbidities
    Chronic kidney dysf. 1035 (41) 211 (15) 780 (73) <0.001
    eGFR 68±26 79±23 54±22 <0.001
    Anemia 727 (29) 124 (9) 589 (55) <0.001
    Hemoglobin 13.4±1.9 14.1±1.5 12.6±1.9 <0.001
    Diabetes 934 (29) 165 (12) 697 (54) <0.001
    COPD 484 (15) 75 (5) 363 (31) <0.001
    Stroke 337 (11) 52 (4) 244 (21) <0.001
    Sleep apnea 128 (4) 19 (1) 104 (9) <0.001
    Hypothyroidism 272 (9) 37 (3) 199 (18) <0.001
    Hyperthyroidism 101 (3) 21 (2) 68 (6) <0.001
JVP=jugular venous pressure; SBP=systolic blood pressure; AF=atrial fibrillation; ICD=implantable cardiovert-
er; CRT(-D)=cardiac resynchronization therapy(-defibrillator); ACE-i=angiotensin-converting enzyme-inhib-
itor; ARBs=angiotension II receptor blockers, COPD=chronic obstructive pulmonary disease; eGFR=estimated 
glomerular filtration rate.
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Results 
Mean age of the 3,226 included patients was 66±14 years and 70% were men. Most 
patients were in NYHA-class II or III (56% and 26%) and 41% had an ischemic cause of 
heart failure. Table 1 shows other baseline characteristics of the study cohort. 
Prevalence of co-morbidities
Of all patients, 74% had at least one co-morbidity. CKD (41%), anaemia (29%) and dia-
betes (29%) were the co-morbidities with the highest prevalence (Table 1). COPD (15%) 
and stroke (11%) were also common. Sleep apnoea had a prevalence of 4%. Hypothy-
roidism (9%) was more prevalent than hyperthyroidism (3%). Of all patients, only 26% 
(N=610) had no co-morbidity, 30% had 1 co-morbidity, 23% had 2 co-morbidities and 
43% had 2 or more co-morbidities. 
Characteristics of patients with multiple co-morbidities
Patients with co-morbidities were older (P<0.001) and had a higher NYHA class 
(P<0.001). When multiple co-morbidities were present, patients were more likely to 
have heart failure due to ischemic aetiology (P<0.001) with hypertension (P<0.001) and 
Figure 1. The prevalence of multiple comorbidities. Blue bars are the percentages of the number of comorbidi-
ties. The red bars are the cumulative percentages. 
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atrial fibrillation (P<0.001). Although more frequently treated with diuretics (P<0.001), 
patients with multiple co-morbidities received less ACE-inhibitor, angiotensin receptor 
blocker and beta-blocker therapy (all P<0.001).
Of all patients without co-morbidities, 15% had clinical signs of congestion (elevated 
jugular venous pressure (JVP) >6 cm or peripheral edema); of all patients with 1, 2, 3 
or ≥4 co-morbidities, respectively 24%, 27%, 33% and 36% had clinical signs of either 
elevated JVP or peripheral edema (P<0.001).
Co-morbidities and prognosis
Of all co-morbidities, diabetes, COPD, CKD and anaemia were significantly associated 
with all-cause mortality (Table 2). In multivariable analyses, after adjustment for other 
confounders, CKD (HR 1.50 [95% CI: 1.06-2.11], P=0.0212), anaemia (HR 1.69 [1.22-
2.35], P=0.0017) and diabetes (HR 1.74 [1.28-2.37], P=0.0004) remained significantly 
related with all-cause mortality. COPD (HR 1.37 (0.96-1.94), P=0.0819) was borderline 
significant. 
CKD (HR 1.59 [1.23-2.06], P=0.001), anaemia (HR 1.44 [1.13-1.84], P=0.0034) and dia-
betes (HR 1.31 [1.04-1.65], P=0.0239) were also independently associated with heart fail-
ure hospitalizations, as was hypothyroidism (HR 1.46 [1.06-2.01], P=0.0221) (Table 3).
Confirming these findings, the prognostic implication for the whole population was 
highest for CKD, with a population attributable risk (PAR) of 41% (95% CI: 29-51%). In 
other words, 41% (29-51%) of all-cause mortality in the population is attributable to the 
co-morbidity CKD. Anaemia had the second highest PAR of 37% (27-46), followed by 
diabetes (14% [5-23]) and COPD (10% [3-16]). All other co-morbidities had a mean PAR 
below 5%. In terms of mortality, 18 patients without co-morbidities (1%), 171 patients 
Table 2. Univariate and multivariate associations between comorbidities and all-cause mortality.
Univariate Multivariate
N deaths (%) HR (95% CI) P value HR (95 % CI) P-value
   Chronic kidney dysf. 130 (5%) 2.77 (2.08-3.69) <0.0001 1.50 (1.06-2.11) 0.0212
   Anemia 107 (4%) 3.12 (2.36-4.12) <0.0001 1.69 (1.22-2.35) 0.0017
   Diabetes 90 (3%) 1.57 (1.21-2.04) <0.0001 1.74 (1.28-2.37) 0.0004
   COPD 52 (2%) 1.76 (1.29-2.40) <0.0001 1.37 (0.96-1.94) 0.0819
   Stroke 32 (1%) 1.35 (0.93-1.97) 0.1109 1.20 (0.79-1.82) 0.3873
   Sleep apnea 8 (0%) 0.85 (0.42-1.72) 0.6509 1.00 (0.48-2.06) 0.9894
   Hypothyroidism 27 (1%) 1.47 (0.98-2.19) 0.0617 1.31 (0.83-2.07) 0.2412
   Hyperthyroidism 10 (0%) 1.41 (0.75-2.65) 0.2915 1.16 (0.58-2.30) 0.6720
Multivariate hazard ratio’s (HR) are corrected for age, gender, etiology, hypertension, atrial fibrillation, conges-
tion, body surface area, systolic blood pressure and heart rate per comorbidity.
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with at least one co-morbidity (7%), including 27 patients (1%) with more than three 
co-morbidities, died. Figure 2 shows that patients with 1-3 co-morbidities have a higher 
mortality rate (HR 3.24 [1.99-5.30], P<0.001) and higher rates of heart failure hospitaliza-
tions (HR 1.95 [1.44-2.64], P<0.001) than patients without co-morbidities. Patients with 
>3 co-morbidities had an even higher mortality rate (HR 9.33 [5.14-16.96], P<0.001) 
and were re-hospitalized more frequently (HR 4.74 [3.10-7.23], P<0.001) than patients 
without co-morbidities.
Geographical regions
In figure 1 the prevalence of co-morbidities is divided into European regions. Eastern 
European patients (n = 363) had less CKD (28% vs. 39%, 43% and 42%) compared to 
Northern (n = 501), Southern (n = 2025) and Western (n = 337) European regions re-
spectively. The prevalence of anaemia was much lower in Eastern European patients (17% 
vs. 29%, 32% and 24%). Northern European patients had a much lower prevalence of 
diabetes (16% vs. 32%, 33% and 29%) compared to Southern, Western and Eastern Euro-
pean regions, respectively. Geographical differences were minimal for hyperthyroidism, 
stroke and COPD. Hypothyroidism was twice as common in Southern and Western Eu-
Figure 2. The prevalence of multiple comorbidities per geographical regions in Europe (East, North, South and 
West).
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ropean countries (both 10% vs. 5% and 6%). Sleep apnoea was diagnosed more often in 
Western European countries (10% vs. 2%, 2% and 4%).
Overall, patients from the Northern European countries had fewer co-morbidities 
(72%) than Western European countries (77%), followed by Eastern (78%) and Southern 
European countries (80%). 
Discussion
This study examines multiple co-morbidities in a broad spectrum of patients in chronic 
heart failure. In this pilot survey, we found that the majority of patients had a least one co-
morbidity, and the number of co-morbidities increased with the severity of heart failure. 
Diabetes, CKD and anaemia had the highest prevalence and were independently associ-
ated with both mortality and HF hospitalization. 
Prevalence of co-morbidities
CKD, anaemia and diabetes were the most common co-morbidities in our chronic heart 
failure patients, along with COPD and stroke. These findings are consistent with other 
reports.11-14 
In the absence of active screening, we found a much lower prevalence for sleep apnoea 
in our population, in stark contrast with the prevalence of up to 60% reported in recent 
literature.15-22 This discrepancy underscores the need for better screening for co-morbid-
ities, particularly in cases where symptoms overlap with those of heart failure. The same 
holds true for COPD, where prevalence is reported up to 50%.23,24 In another study, only 
43% of patients with evidence of COPD during spirometry self-reported having COPD.25
Table 3. Univariate and multivariate associations between comorbidities and heart failure hospitalization. 
Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
    Chronic kidney dysf. 2.16 (1.75-2.66) <0.0001 1.59 (1.23-2.06) 0.0005
    Anemia 2.12 (1.72-2.61) <0.0001 1.44 (1.13-1.84) 0.0034
    Diabetes 1.47 (1.21-1.79) <0.0001 1.31 (1.04-1.65) 0.0239
    COPD 1.45 (1.14-1.84) 0.0026 1.09 (0.82-1.44) 0.5745
    Stroke 1.17 (0.88-1.57) 0.2844 1.09 (0.79-1.52) 0.5839
    Sleep apnea 1.22 (0.78-1.91) 0.3742 0.94 (0.56-1.58) 0.8156
    Hypothyroidism 1.66 (1.25-2.21) <0.0001 1.46 (1.06-2.01) 0.0221
    Hyperthyroidism 1.20 (0.73-1.97) 0.4753 1.07 (0.64-1.81) 0.7877
Same abbreviations and multivariate models as Table 3.
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Figure 3b. HF-hospitalization among groups of multiple comorbidities for. Groups are defined by 0 comorbidi-
ties, 1-3 comorbidities and >3 comorbidities.
Figure 3a. Mortality among groups of multiple comorbidities. Groups are defined as 0 comorbidities, 1-3 co-
morbidities and >3 comorbidities. 
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We found that hypothyroidism had a higher prevalence compared to hyperthyroidism. 
This could be due to the effect of amiodarone therapy on thyroid dysfunction. In patients 
with persistent atrial fibrillation, hypothyroidism has been reported to have a prevalence 
of 31% in those treated with amiodarone compared to 7% in the control group.26
We found a high prevalence of co-morbidities in patients with chronic heart failure - 
Nearly half had two or more co-morbidities. In a cross-sectional study of 122,630 patients 
with heart failure, the prevalence of co-morbidities was even higher.5 This difference is 
likely due to the greater number of co-morbidities assessed in the cross-sectional study. 
Determinants of co-morbidities
Literature shows a high prevalence of co-morbidities in patients with heart failure. Al-
though co-morbidities might cause heart failure, it is reasonable to believe that heart fail-
ure itself might be a cause of multiple other co-morbidities.6 This is supported by the find-
ing that the prevalence of co-morbidities is associated with the severity of heart failure, 
measured with the New York Heart Association (NYHA) functional classification.27 Next 
to neurohormonal changes and the negative effect of heart failure medication, hemody-
namic factors could play a pathophysiological role as well.13,28-31
We found that patients with co-morbidities were older and had more advanced heart 
failure, reflected by a higher NYHA class and a higher prevalence of hypertension and 
atrial fibrillation, although a causal relationship cannot be established based on the data. 
Patients with heart failure of ischemic aetiology had more co-morbidities, and patients 
with more co-morbidities had more clinical signs of congestion (elevated JVP or periph-
eral edema). This is consistent with our previous findings that congestion plays a patho-
physiological role in renal and liver dysfunction.13,31 Organs in heart failure may also be 
affected by impaired hemodynamics, reflected by elevated venous pressure, among other 
factors.6
Importantly, we found that patients with co-morbidities were less likely to be receiv-
ing evidence-based therapies, such as ACE-inhibitors, angiotensin receptor blockers and 
beta-blockers. In accordance, previous studies have shown thatsicker patients are more 
likely to have side effects or contraindications.32-34
Population attributable risk
The term attributable risk is the difference in the rate of a condition (for instance mor-
tality) between an exposed population and an unexposed population (presence or ab-
sence of a co-morbidity). Attributable risk was first described in 1953 and has been used 
since.10,35 Interestingly, attributable risks combine incidence with effect. For our analyses, 
population attributable risk can be described as the reduction in mortality that would be 
observed if the population was entirely unexposed to a certain co-morbidity, compared 
with the mortality pattern in patients without that co-morbidity. 
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When co-morbidities were considered separately, we found that CKD and anaemia had 
the highest PAR. All-cause mortality could also be attributed to diabetes and stroke, while 
other co-morbidities lacked a significant PAR. The high PARs for CKD and anaemia are 
driven by the combination of high prevalence and a strong association with mortality. 
Prognosis and co-morbidities
Previous studies have shown a strong association between co-morbidities and adverse 
clinical outcomes.3,4,11 It has been calculated that patients with five or more co-morbidi-
ties are responsible for 81% of all hospital days experienced by all heart failure patients.5 
Our findings confirm that patients with increasing numbers of co-morbidities have an 
increasing risk of both mortality and heart failure hospitalization.
Accordingly, we found that CKD, anaemia and diabetes remained significantly and in-
dependently related to all-cause mortality and heart failure hospitalizations. This is in 
accordance with other studies reporting on CKD and anaemia separately. This supports 
a causal relationship between heart failure and co-morbidities, linking them to disease 
severity.
Diabetes was also associated with a poorer prognosis in heart failure. In acute heart fail-
ure, diabetic patients had worse outcome compared to non-diabetics.36 The relationship 
with prognosis is less clear in patients with chronic heart failure.37-39 
Regarding sleep apnoea, we did not find an association with outcome in the present 
study, although other studies show that sleep apnoea is associated with increased mortal-
ity.40,41 We believe that this difference can be explained by underreporting due to a lack 
of screening, as explained previously. Other studies show that, after adjustment for con-
founders, sleep apnoea doubles the mortality risk in patients with heart failure.40,41
Geographical regions
Patients from the Northern European countries were less likely to have co-morbidities, 
followed by Western, Eastern and Southern European countries, in ascending order. This 
was largely driven by diabetes, which had a low prevalence in Northern European coun-
tries compared to the other regions. However, patients from Eastern European countries 
were less likely to have CKD and anaemia. Hypothyroidism was slightly more commonly 
diagnosed in Southern and Western Europe, while sleep apnoea was more commonly 
diagnosed in Western Europe. 
In addition to prevalence, there were also marked regional differences in the prognos-
tic implications of co-morbidities. In Eastern and Northern European patients, all-cause 
mortality was less attributable to diabetes, COPD and CKD, compared to patients from 
Southern and Western European patients. In Southern and Northern European coun-
tries, mortality was less attributable to stroke.
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Limitations
 As is the case for all surveys, the voluntary participation and recruitment of pa-
tients imposes limitations that must be acknowledged. First, as mentioned in the main ar-
ticle, this pilot study tried to balance the methodological need for consecutive enrolment 
with the practical feasibility by reducing the workload for centres with limited recruit-
ment to 1 day per week for 8 months. Second, the study population may not represent 
the general heart failure population. Participating centres were selected proportionally 
to the size of the population of the participating countries, accounting for the different 
technological levels of the cardiology centres invited to participate. Another important 
limitation is that the diagnosis of heart failure was made by the treating physician, and 
both diagnosis and events were not adjudicated.
 There are many potential explanations for the regional differences observed. 
These include a lack of screening for co-morbidities in various regions of Europe, or im-
perfect representativeness of the regional populations. Hospital care practices also dif-
fer between countries and centres. However, the observed differences may also be ‘real’ 
and thus related to the heterogeneous European epidemiology, with regional variation in 
prevalence, cardiovascular risk factors and cardiovascular event rates.42 
Conclusion
This is the first study to examine multiple co-morbidities in a broad spectrum of patients 
with chronic heart failure. This pilot survey showed that the majority of patients had a 
least one co-morbidity, with CKD, anaemia and diabetes being most prevalent, and that 
the number of co-morbidities increased with the severity of heart failure. Diabetes, CKD 
and anaemia were independently associated with both mortality and HF hospitalization. 
However, there were marked differences in prevalence and prognostic implications of co-
morbidities across various European regions.
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Chapter 2
Renal Function and Hemodynamics
Kevin Damman, Vincent M. van Deursen, Gerjan Navis, 
Adriaan A. Voors, Dirk J. van Veldhuisen and Hans L. Hillege
Increased central venous pressure is associated with impaired 
renal function and mortality in a broad spectrum of patients 
with cardiovascular disease
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Abstract
Objectives
We sought to investigate the relationship between increased central venous pressure 
(CVP), renal function, and mortality in a broad spectrum of cardiovascular patients.
Background
The pathophysiology of impaired renal function in cardiovascular disease is multifacto-
rial. The relative importance of increased CVP has not been addressed previously.
Methods
A total of 2,557 patients who underwent right heart catheterization in the University 
Medical Center Groningen, the Netherlands, between January 1, 1989, and December 31, 
2006, were identified, and their data were extracted from electronic databases. Estimated 
glomerular filtration rate (eGFR) was assessed with the simplified modification of diet in 
renal disease formula.
Results
Mean age was 59 ± 15 years, and 57% were men. Mean eGFR was 65 ± 24 ml/min/1.73 
m2, with a cardiac index of 2.9 ± 0.8 l/min/m2 and CVP of 5.9 ± 4.3 mm Hg. We found 
that CVP was associated with cardiac index (r = -0.259, p < 0.0001) and eGFR (r = -0.147, 
p < 0.0001). Also, cardiac index was associated with eGFR (r = 0.123, p < 0.0001). In 
multivariate analysis CVP remained associated with eGFR (r < -0.108, p < 0.0001). In a 
median follow-up time of 10.7 years, 741 (29%) patients died. We found that CVP was an 
independent predictor of reduced survival (hazard ratio: 1.03 per mm Hg increase, 95% 
confidence interval: 1.01 to 1.05, p = 0.0032).
Conclusions
Increased CVP is associated with impaired renal function and independently related to 
all-cause mortality in a broad spectrum of patients with cardiovascular disease. 
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Introduction
Renal dysfunction is a strong and independent predictor of prognosis in the general 
population but also in patients with diabetes, hypertension, coronary artery disease, 
and heart failure.1-7 The pathophysiology is multifactorial and associated with decreased 
renal perfusion, atherosclerosis and inflammation, endothelial dysfunction, and neuro-
hormonal activation.8-10 We recently showed that in patients with cardiac dysfunction 
secondary to pulmonary hypertension, not only was renal perfusion strongly associated 
with renal function impairment but also with venous congestion.11 However, it is unclear 
whether this observation is limited to those patients with reduced cardiac function and 
pulmonary hypertension or whether it also may be present in patients with a mixture 
of cardiovascular diseases with varying etiologies and treatments. In addition, there are 
only limited data on the relationship between venous congestion, as estimated by central 
venous pressure (CVP) and the impact on prognosis, even in patients with and without 
heart failure. The studies that have been conducted are either small or include only non-
invasive assessment of increased venous congestion, such as jugular venous pressure.12-15 
In the present study, we therefore aimed to investigate the relationship between CVP, 
renal function, and mortality in patients with a mixture of cardiovascular diseases with 
varying etiologies and treatments.
Methods
Case identification
Using the patient registration system of the University Medical Center Groningen, the 
Netherlands, all patients that underwent right heart catheterization between January 1, 
1989, and December 31, 2006, were identified.
Data extraction
Retrospective chart review was performed to analyze characteristics of all patients that 
were identified during the electronic search. For each patient, date of birth, sex, race, 
and weight and height were collected. Comorbid conditions, including hypertension, 
coronary artery disease, cardiac valve disease, congenital heart disease, history of stroke, 
hypercholesterolemia, and diabetes, in addition to medical treatment at the time of cath-
eterization also were extracted for each patient. Furthermore, the reason for performing 
right heart catheterization was identified. The study was approved by the institutional 
review board of the University Medical Center Groningen.
Heart catheterization
Hemodynamic variables obtained during catheterization included systolic blood pres-
sure (mm Hg), diastolic blood pressure (mm Hg), cardiac output (thermodilution, l/
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min), and right atrial pressure as indicator of CVP (CVP, mm Hg). Cardiac index (l/
min/m2) was determined as cardiac output divided by the body surface area, which was 
calculated as: 0.007184 · weight 0.425 · length 0.725. Measurements obtained from cardiac 
catheterization were obtained from the patient during a resting state.
Renal function measurement
Serum creatinine at the day of catheterization was extracted. For the patients who did 
not have laboratory measurements on the day of catheterization, measurements obtained 
within 3 days before catheterization were taken as the baseline value. Of patients includ-
ed in the study, 2,282 (89%) had at least 1 serial creatinine measurement within 3 days 
of catheterization. Renal function was estimated as glomerular filtration rate (GFR) by 
using the simplified modification of diet in renal disease equation (estimated glomeru-
lar filtration rate [eGFR] [ml/min/1.73 m2] · 186.3 · [serum creatinine] -1.154 · age -0.203 · 
[0.742 if female]).16 Estimated GFR values >200 ml/min/1.73 m2 were set equal to 200 ml/
min/1.73 m2, according to Coresh et al.17
Mortality data
Survival status was determined using the electronic patient registration database of the 
University Medical Center Groningen. Follow-up started directly after right heart cath-
eterization. The primary end point consisted of death from any cause.
Statistical analysis
Data are given as mean ± standard deviation when normally distributed, as median 
and interquartile range when skewed distributed, and as frequencies and percentages for 
categorical variables. Associations between baseline variables were evaluated by means 
of 1-way analysis of variance, the Kruskal-Wallis test, and chi-square or Fisher exact 
tests, when appropriate. Two-sided p values were used, taking p < 0.05 to be statistically 
significant. CVP was divided into tertiles to assess relationships between baseline char-
acteristics and CVP. A fractional polynomial parameterization of exposure was used to 
explore nonlinearity between different predictors and renal function. In this technique, 
each exposure value is expressed as a polynomial of degree >1 (e.g., quadratic, cubic, and 
so on), yielding an estimated model with multiple predictors (i.e., separate predictors for 
the linear, quadratic, terms, respectively). We used a Cox proportional hazards survival 
model to estimate hazard ratios (HRs) with 95% confidence intervals (CIs). At first, in 
multivariate analysis, CVP was fitted into a stepwise multivariate Cox regression analysis 
on a continuous scale. In secondary analysis, CVP was fitted into the model and, in multi-
ple steps, the model was adjusted for other variables and parameters. The internal validity 
of the regression model was assessed by the bootstrap resampling technique.18 For each of 
100 bootstrap samples, the model was refitted and tested on the original sample to obtain 
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a bias-corrected estimate of predictive accuracy. Statistical analyses were performed us-
ing SPSS version 12.0 (Chicago, Illinois) and STATA version 9.0 (College Station, Texas).
Results
Baseline characteristics
A total of 3,757 right heart catheterizations were conducted between 1989 and 2006. Of 
these, 2,557 (68%) were first or only right heart catheterization of unique patients and 
formed the study population. Main reasons for right heart catheterization are shown in 
Table 1. Aortic and mitral valve disorders accounted for 44% of indications, whereas in 
16%, acute or chronic heart failure was the predominant reason. Mean age was 59 ± 15 
years, and 57% were men (Table 2). In the total study population, both mean cardiac in-
dex (2.9 ± 0.8 l/min/m2) and mean CVP (5.9 ± 4.3 mm Hg) were within the normal range. 
The distribution of CVP among the study population is shown in Figure 1. Mean eGFR 
was moderately impaired: 65 ± 24 ml/min/1.73 m2.
The distribution of different factors over tertiles of CVP is shown in Table 2. Most of 
the characteristics were equally distributed across tertiles of CVP, except for the highest 
tertile (CVP >6 mm Hg). Both cardiac output and cardiac index were significantly lower 
Table 1. Primary Indication for Heart Catheterization.
Percentage of Patients
Aortic valve disorders 29
     Aortic valve stenosis 23
     Aortic valve insufficiency 6
Mitral valve disorders 15
     Mitral valve insufficiency 14
     Mitral valve stenosis 1
Pulmonary valve disorders 1
     Pulmonary valve insufficiency 0.8
     Pulmonary valve stenosis 0.2
Heart failure 16
Coronary artery disease 13
Pre transplantation (non-cardiac) 11
Rhythm disorders 5
Pulmonary hypertension 3
Congenital heart disease 2
Post heart transplantation 2
Other 6

































































































































































































































































































































































































































































































































































































































in the highest tertile compared with lower tertiles (p < 0.0001), corresponding to r = 
-0.259 (p < 0.0001) for the association between CVP and cardiac index. Furthermore, 
patients in the highest tertile were treated more frequently with angiotensin-converting 
enzyme inhibitor/angiotensin-II receptor blockers, beta-blockers, diuretics, and aldoster-
one antagonists. Prevalence of heart failure showed a trend toward increasing with higher 
tertiles of CVP (p = 0.0781), whereas congenital heart disease was also more prevalent 
in the highest tertile. Finally, eGFR was significantly lower in the highest tertile of CVP, 
compared with both lower tertiles (p < 0.001).
Curvilinear fitting and the relationship between CVP and eGFR. 
Figure 1 shows the curvilinear relationship between CVP and eGFR in the total study 
population as obtained by fractional polynomial modeling. Estimated GFR showed a 
small increase when CVP increased from 1 to 6 mm Hg. However, in CVP values >6 
mm Hg, a steep decrease is observed with increasing CVP values. This finding resulted 
in a partial correlation of r = 0.064, p = 0.0218 in patients with CVP >6 mm Hg, and r = 
-0.212, p < 0.0001 in patients with CVP >6 mm Hg (adjusted for age, sex, and cardiac in-
Figure 1. Distribution of CVP and Curvilinear Relationship Between CVP and eGFR in the Study Population. 
Adjusted for age, sex, and cardiac index. The curvilinear model had the following individual polynomial com-
ponents for the relationship between CVP and eGFR: First order: Y = -25.8 · (CVP + 1) / 10 (Wald 28.2, P < 
0.0001) and second order: Y = 35.7 · ((CVP + 1) / 10) 0.5 (Wald 17.4, p < 0.0001). CVP = central venous pressure; 
eGFR = estimated glomerular filtration rate.
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dex). On a continuous scale, CVP was also significantly associated with eGFR (r = -0.110, 
p < 0.0001) after transformation.
Besides CVP, age (r = -0.438, p < 0.0001), sex (r = 0.137, p < 0.0001), and cardiac index 
(r = 0.249, p < 0.0001) were associated with eGFR. In addition, lower eGFR values also 
were found to be related with the use of any type of cardiovascular medication and a his-
tory of diabetes and hypertension. There was a significant interac- tion between CVP and 
cardiac index on the relationship with eGFR. The observed biphasic relationship between 
CVP and eGFR was most pronounced in patients with relatively normal cardiac index 
(Figure 2).
In multivariate analysis, CVP remained associated with eGFR (r = -0.108, p < 0.0001, 
adjusted for covariates), which was confirmed by bootstrap analysis (Online Table 1). 
After adjustment for the year of catheterization, the association between CVP and eGFR 
was numerically unchanged: r = -0.105, p < 0.0001. Excluding patients with a history of 
heart transplantation, who were likely to receive renal function compromising immu-
notherapy, CVP remained associated with eGFR (r = -0.108, p < 0.0001) in multivariate 
analysis. Including only patients without heart failure, similar associations were present 
(r = -0.080, p = 0.0034). Excluding both heart transplant recipients and heart failure pa-
Figure 2. Curvilinear Relationship Between CVP and eGFR According to Different Cardiac Index Values. P = 
0.0217 for interaction between cardiac index and CVP on the relationship with eGFR. Solid line = cardiac index 
< 2.5 l/min/m2; dashed line = cardiac index 2.5 to 3.2 l/min/m2; dotted line = cardiac index > 3.2 l/min/m2. CVP 
= central venous pressure; eGFR = estimated glomerular filtration rate.
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tients, the association between CVP and eGFR remained (r = -0.079, p = 0.0042).
CVP and mortality
Mortality data were available in all patients, whereas time of death was available in 2,424 
(95%) of patients. Median follow-up among survivors was 10.7 years and, during follow-
up, 741 (29%) of the patients died. Crude mortality ranged from 24% in the lowest tertile 
to 29% and 35% in the 2 highest tertiles of CVP (p < 0.0001 for trend). On a continuous 
scale, greater CVP levels were associated with impaired survival (HR: 1.05 per mm Hg 
increase, 95% CI: 1.04 to 1.07, p < 0.0001). Kaplan-Meier survival curves for tertiles of 
CVP are shown in Figure 3, showing that patients with the greatest CVP in particular 
were at risk for increased mortality (HR for CVP >6 mm Hg vs. ≤6 mm Hg: 1.49, 95% 
CI: 1.26 to 1.76, p < 0.0001). Baseline eGFR (HR: 1.09 per 10 ml/min/1.73 m2 decrease, 
95% CI: 1.05 to 1.13, p < 0.0001) and cardiac index (HR: 0.74 per l/min/m2 increase, 95% 
CI: 0.66 to 0.84, p < 0.0001) also were strong predictors of mortality. Other factors as-
sociated with reduced survival are shown in Table 3. In stepwise multivariate Cox regres-
sion analysis, CVP remained significantly associated with reduced survival (HR: 1.03 per 
mm Hg increase, 95% CI: 1.01 to 1.05, p = 0.0032) (Table 3). Finally, we fitted a second 
Figure 3. Kaplan-Meier Analysis of Event-Free Survival According to Tertiles of CVP. HR: 1.22 (95% CI: 1.00 to 
1.49), p = 0.0466 for CVP 4 to 6 mm Hg; HR: 1.65 (95% CI: 1.35 to 2.01), p < 0.0001 for CVP >6 mm Hg, both 
compared with CVP 0 to 3. CI = confidence interval; HR = hazard ratio; CVP = central venous pressure; eGFR 
= estimated glomerular filtration rate.


























































































































































































































































































































































































































































































































































































































































model, adjusting CVP for other covariates (Online Table 2). CVP remained an independ-
ent predictor of impaired survival (HR: 1.03 per mm Hg increase, 95% CI: 1.01 to 1.05, p 
= 0.0144). To account for the effects of changing therapy during the study inclusion time, 
we adjusted for the year of catheterization. This secondary analysis yielded similar results 
(HR: 1.03 per mm Hg increase, 95% CI: 1.00 to 1.05, p = 0.0207). Excluding patients with 
known heart failure and heart transplant recipients, CVP was still associated with mortal-
ity (HR: 1.03 per 5 mm Hg increase, 95% CI: 1.00 to 1.06, p = 0.0369).
Discussion
The present study shows that increased CVP is associated with impaired renal function 
in a broad spectrum of cardiovascular patients who underwent right heart catheteriza-
tion. In addition, the slope between CVP and impaired eGFR was steeper with relatively 
preserved cardiac function. Finally, an increased CVP was a strong and independent de-
terminant of all-cause mortality, which was especially observed in patients with a CVP 
>6 mm Hg.
There are only limited data on the relationship between increased CVP and renal im-
pairment. Studies in animals have shown that increasing renal venous pressure leads to 
a reduction in glomerular filtration, which was probably mediated by a decreased renal 
perfusion.19 Renal vein constriction led to a decrease in GFR in rats,20 whereas renal func-
tion decreased when renal vein pressure was increased in dogs, but only when cardiac 
output was reduced.21 We recently showed that in patients with reduced cardiac func-
tion, secondary to pulmonary hypertension, increased CVP was strongly associated with 
renal impairment, especially when renal perfusion was already impaired.11 Early studies 
on increased renal vein pressure in heart failure patients and animals showed a marked 
reduction in renal blood flow as well as water and salt excretion,22,23 but the effect on GFR 
was not uniform. One small report showed a strong relationship between CVP and renal 
blood flow in advanced heart failure.24
Drazner et al.13 reported that in patients with increased jugular venous pressure on ex-
amination, serum creatinine was significantly greater. In patients who underwent elective 
cardiac surgery, pre-operative presence of high CVP was a strong predictor of the occur-
rence of acute renal injury, independent of the presence of low CO.25
However, especially in patients with preserved cardiac function, data regarding the re-
lationship between CVP and renal function are scarce. Diastolic dysfunction, a disease 
characterized by increased filling pressures, often coexists with renal failure and vice 
versa.26-28 Interestingly, a recent study showed that renal dysfunction is even more impor-
tant in defining mortality risk in patients with preserved cardiac function compared with 
those with systolic dysfunction.29-30 Our present study confirmed that increased CVP is 
an important risk factor for decreased renal function in patients with preserved and de-
creased cardiac function.
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Curvilinear effect of CVP with eGFR
We observed a biphasic relationship between eGFR and increasing CVP. In the physi-
ologic ranges of CVP, up to 6 mm Hg, eGFR increases gradually. This subtle increase 
in eGFR may be a reflection of increased cardiac filling to preserve cardiac function by 
Frank-Starling mechanism (pre-load), and subsequent renal perfusion.31 This gradual in-
crease in eGFR was observed across the full spectrum of low to high cardiac index. We 
observed a decrease in eGFR when CVP increases above 6 mm Hg. In these patients, the 
equilibrium among venous return, CO, and CVP may have shifted toward a plateau phase 
or optimum, where CO is not further increased in response to greater CVP.32 Greater 
CVP levels will then decrease renal perfusion pressure, which will further impair eGFR. 
However, if greater CVP levels preserve CO, and despite this mechanism, eGFR decreases 
with greater CVP, this action suggests that increased CVP also may exert an effect on 
GFR in this group of patients, independent of renal perfusion.
Importantly, the relationship between CVP and GFR is bound to be bidirectional. Not 
only may CVP influence GFR, but even mildly impaired renal function may initiate salt 
and water retention, resulting in increased cardiac filling pressures.33 Because of the 
cross-sectional nature of our analysis, we were unable to investigate the cause-effect as-
sociations, and our present analysis must be regarded as hypothesis generating.
CVP and eGFR in patients with and without cardiac dysfunction
Of particular interest is the interaction between cardiac index and CVP on eGFR. Pa-
tients who have a combination of reduced perfusion (cardiac index) and increased ve-
nous congestion (CVP) suffer from fluid overload and decreased organ perfusion, lead-
ing, among other things, to renal dysfunction. We showed that patients with high CVP 
levels often also have decreased cardiac index and reduced eGFR. Remarkably, CVP and 
cardiac index showed an interaction on the relationship with eGFR, with an even more 
pronounced relationship in patients with relatively normal cardiac index. This further 
strengthens the observation of a relationship between CVP and eGFR, which is not exclu-
sively due to reduced cardiac systolic function. It also challenges the intuitive notion that 
fluid overload, although deleterious from a cardiovascular perspective, will invariably be 
beneficial from the point of view of preservation of renal function. Because our analysis 
does not allow to dissect cause and effect relationships, however, it might also well be that 
the relatively normal cardiac index is maintained at the expense of the increased CVP. 
In that case, apparently, such a renal hemodynamic profile does not translate into better 
renal function. Our present findings seem inconsistent with our earlier findings, showing 
that patients with reduced renal perfusion in particular are prone to a detrimental effect 
of CVP on GFR.11 However, we did not measure renal hemodynamics or renal function 
by clearance techniques in the present study, and the population was also different. Fur-
thermore, our previous study consisted of patients with much lower cardiac indexes, all of 
which makes a comparison difficult. Nevertheless, this inconsistency needs to be further 
addressed in future studies.
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New therapeutic agents in the treatment of acute heart failure that are specifically tar-
geted at improvement of cardiac function and reducing venous congestion recently have 
shown promising results regarding renal function. A substudy of the SURVIVE (Survival 
of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support) study, in 
which levosimendan was compared with dobutamine, showed that improvement of renal 
function was more pronounced in the group receiving levosimendan, despite the obvious 
positive inotropic effect of dobutamine.34 The specific venodilatory effect observed with 
levosimendan, with subsequent reduced CVP, may be the pathophysiologic mechanism, 
supporting a direct pathophysio- logic link between CVP and renal impairment.35
CVP and mortality
Increased CVP and jugular venous pressure predispose to the development of heart 
failure in patients with cardiac dysfunction and have been associated with reduced sur-
vival in patients with heart failure.12,13,36 Small studies have shown that invasive assess-
ment of CVP is a predictor of cardiovascular outcome in patients with advanced heart 
failure.14,15 In other selected patient populations, such as patients who underwent Fontan 
surgery or lung transplantation, greater CVPs were strong predictors of outcome.37,38 The 
prognostic importance of increased CVP in patients with normal cardiac function has 
not been reported previously. We show that in a selected patient population, increased 
CVP remained a determinant of all-cause mortality, independent of cardiac function. 
This association with mortality was most prominent in patients with severely increased 
CVP, even after adjustment for other baseline characteristics. This finding was additive to 
the observation that greater CVP levels predispose to lower eGFR, which may influence 
survival by different mechanisms.
Clinical implications
Increased CVP frequently is observed in patients with and without reduced cardiac 
function, comprising almost 20% of patients in the present patient population. Recog-
nition of these patients is essential because not only is renal dysfunction much more 
frequently observed, but the risk of mortality also increases with increasing CVP levels. 
Treatment to selectively lower CVP may be favorable to reduce symptoms and signs of 
congestion, improve GFR, and improve prognosis.
Study limitations
The present study comprises a selected patient population that had a specific indication 
for right heart catheterization. Patients undergoing right heart catheterization are prone 
to have greater right-sided filling pressures, and the present observations may therefore 
not represent the general cardiovascular population. However, this is a large cohort study, 
with invasive cardiac function and CVP measurements across the full range. Second, this 
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is a retrospective analysis, and no invasive data are available on renal blood flow and true 
GFR in these patients. Furthermore, it should be addressed that our study population 
had very different catheterization indications, medical history, and medication regime, 
all of which could have influenced our results. In our study, the presence of heart failure 
was a clinical diagnosis, rather than related to reduced cardiac index on catheterization. 
Therefore, the prevalence of heart failure in our study is most likely underestimated. The 
relationship between increased CVP and renal perfusion has been observed in heart fail-
ure. However our present study is the first to show an independent effect of CVP on renal 
function. Finally, the retrospective nature of this study and the cross-sectional design 
limited our ability to investigate the cause-effect relationship between renal impairment 
and increased CVP, which may actually mutually influence each other.
Conclusion
Increased CVP is associated with impaired renal function and is independently related 
to all-cause mortality in a broad spectrum of patients with cardiovascular disease.
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Prognostic Value of Plasma NGAL for Mortality 




In patients with heart failure (HF), renal dysfunction is associated with a poor outcome. 
We aimed to assess the prognostic value of plasma Neutrophil Gelatinase Associated 
Lipocalin (NGAL), a novel marker of renal tubular damage, in HF patients with or with-
out renal dysfunction, and compare it with two frequently used biomarkers of chronic 
kidney disease.
Methods
Plasma NGAL, estimated GFR (eGFR) and cystatin C were assessed in 562 heart failure 
patients. Chronic kidney disease was defined as eGFR<60 mL/min/1.73 m2. Outcome 
was all-cause mortality at 36 months.
Results
Mean age was 71±11, 61% were men and 97% were in New York Heart Association 
functional class II/III. Mean baseline eGFR was 54±20 mL/min/1.73 m2, mean cystatin 
C was 11.2 (7.7-16.2) mg/L and median plasma NGAL was 85 (60-123) ng/mL. Higher 
plasma NGAL levels were independently associated with an increased risk of all cause 
mortality, in patients with and without chronic kidney disease (HR (per SD increase in 
log NGAL)=1.45 [1.22-1.72], P<0.001 & HR=1.51 [1.06-2.16], P=0.023 respectively). 
Similarly, both in patients with high and low cystatin C (median cut-off), higher plasma 
NGAL levels were independently associated with an increased risk of all cause mortality. 
Moreover, when NGAL was entered in the multivariable risk prediction model, eGFR 
(P=0.616) and cystatin C (P=0.937) were no longer associated with mortality.
Conclusions
Plasma NGAL predicts mortality in heart failure patients, both in patients with and 
without chronic kidney disease, and is a stronger predictor for mortality than the estab-
lished renal function indices eGFR and cystatin C.
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Introduction
Moderate to severe chronic kidney disease (CKD), mainly expressed by estimated 
glomerular filtration rate (GFR) <60 ml/minute/1.73 m 2, is strongly associated with in-
creased mortality among patients with heart failure whereas these findings are far less 
established in the presence of mild impaired renal function.1,2 
Interestingly, serum creatinine is relatively insensitive to changes in the GFR and kidney 
disease is not only reflected by GFR. In patients with intrinsic kidney failure, tubulointer-
stitial damage is an established marker for renal disease as well.3 In different etiologies of 
kidney failure, tubulointerstitial hypoxia seems to be an early marker for the development 
of kidney failure.4-13 Several studies showed that tubular markers are increased before an 
increase of creatinine is observed.14-17
We recently demonstrated that urinary markers of tubular damage, such as N-acetyl-
beta-D-glucosaminidase (NAG), kidney injury molecule 1 (KIM-1) and Neutrophil Ge-
latinase Associated Lipocalin (NGAL), were elevated in patients with heart failure.3,18 In 
addition, the tubular markers urinary NAG and KIM-1 were related to a poor prognosis, 
independent of eGFR.19 Also, in a much larger sub study of the GISSI-HF trial, urinary 
NGAL levels were independently associated with cardiovascular outcome.19 Few studies 
in heart failure patients have indicated that higher plasma markers of tubular damage are 
also related to an increased risk of mortality.20-24
However, the prognostic value of plasma tubular damage in patients with normal or 
mildly impaired renal function has been less well described.23 The aims of this study were 
firstly to assess the role and performance of the tubular marker plasma NGAL as a prog-
nostic marker of mortality in heart failure patients with both normal and impaired renal 
function. Secondly, we aimed to compare the prognostic value of plasma NGAL with two 
frequently used biomarkers of CKD.
Methods
Patient population
This is a retrospective analysis of the Coordinating study evaluating Outcomes of Advis-
ing and Counseling in Heart failure (COACH), a multicenter, randomized, open trial, de-
signed to compare usual care, basic support and intensive support in patients with heart 
failure, conducted between 2002 and 2007 in The Netherlands.25,26 Patients were included 
just before discharge of their hospitalization for acute decompensated heart failure. The 
study was conducted in accordance with the guidelines of the Declaration of Helsinki 
and approved by the locally appointed ethics committees. All patients provided written 
informed consent for the main study. Of all 1023 patients from the COACH, 562 patients 
had baseline plasma available for this analysis. Demographic and clinical data were col-
lected from chart review.
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Renal function 
We calculated estimated GFR (eGFR, mL/min/1.73 m2) using the simplified Modifica-
tion of Diet in Renal Disease formula (186.3 x (serum creatinine (mg/dL))-1.154 x age-0.203 
x (0.742 if female))27 at discharge and after 6 months. Cystatin C was measured using 
a Luminex assay by Alere San Diego (R&D). Plasma NGAL was measured using a si-
multaneous enzyme-linked immunosorbent assay (ELISA). The primary antibody was 
biotinylated and bound to a neutravidin plate.  The secondary antibody was labeled with 
fluorescein, which serves as a hapten for an anti-fluoroscein antibody labeled with alka-
line phosphatase (AP). All other liquid handling steps were performed with a Beckman 
Biomek FX.
Other biomarkers 
To account for the possible inflammatory association of NGAL, C-reactive protein was 
measured using a bead-based immunoassay performed in microtiter plates.  The primary 
antibody was conjugated to modified paramagnetic Luminex beads obtained from Radix 
Biosolutions; purified C-reactive protein was biotinylated.  
B-type natriuretic peptide (BNP) was measured using a bead-based immunoassay 
performed in microtiter plates. The primary antibody was conjugated to modified para-
magnetic Luminex beads obtained from Radix Biosolutions; the secondary antibody was 
biotinylated.  Fluorescent signals were generated using Streptavidin-R-Phycoerythrin 
(SA-RPE: Prozyme PJ31S).  
Outcome 
The extended outcome of the COACH trial consisted of mortality assessed at 36 months, 
for which additional ethical committee approval was obtained.
Statistical analyses 
Patients were divided into two groups according to the value of eGFR: the CKD group 
(eGFR < 60 ml/min/1.73 m2 by Modification of Diet in Renal Disease (MDRD) equation) 
and the non-CKD group (eGFR ≥ 60 ml/min/1.73 m2). Because previous research sug-
gests a difference in risk curves for CKD and non-CKD heart failure patients the analy-
ses were conducted separately by the presence of CKD.2 Data are presented as mean ± 
standard deviation when normally distributed, as median and interquartile range when 
non-normally distributed and as frequencies and percentages for categorical variables. 
Differences between baseline variables were evaluated by Student’s t test, Kruskal-Wal-
lis test, Mann-Whitney U or chi-square tests where appropriate. For the Kaplan-Meier 
curves, CKD classification and medians of plasma NGAL and cystatin C were used as 
cut-off points. 
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Age (years) 71 ± 11 74 ± 10 66 ± 11 < 0.001
Gender (% female) 39 42 33 0.005
LVEF (%) 32 ± 14 33 ± 14 32 ± 15 0.493
NYHA (%) < 0.001
   2 47 39 59
   3 50 57 39
   4 3 4 2
Systolic BP (mmHg) 118 ± 21 119 ± 22 116 ± 20 0.067
Diastolic BP (mmHg) 69 ± 12 68 ± 12 70 ± 12 0.122
Heart rate (bpm) 74 ± 13 74 ± 13 75 ± 13 0.43
Medical history (%)
    Hypertension 42 49 31 < 0.001
    Peripheral arterial disease 16 18 12 0.009
    Myocardial infartion 41 45 34 0.044
    Atrial fibrillation 45 49 40 0.014
    Stroke 15 18 11 0.061
    COPD 28 31 24 0.084
Laboratory
    Cystatin C (mg/l) 11.2 ( 7.7-16.2 ) 12.6 ( 8.7-19.2 ) 8.8 ( 7-12.6 ) < 0.001
    NGAL (ng/ml) 85 ( 60-123 ) 104 ( 72-151 ) 65 ( 51-85 ) < 0.001
    Creatinine (µmol/l)* 115 ( 91-145 ) 138 ( 117-167 ) 87 ( 77-101 ) < 0.001
    Hemoglobin (g/dl) 13 ± 2 12.8 ± 1.9 13.7 ± 2 < 0.001
    BNP (pg/ml) 454 ( 202-904 ) 480 ( 214-997 ) 416 ( 185-785 ) 0.078
    CRP (mg/l) 2.3 ( 0.9-5.1 ) 2.3 ( 1-5.5 ) 2.3 ( 0.8-4.9 ) 0.093
Medication use (%)
    ACE inhibitor 72 68 79 < 0.001
    Angiotensin receptor blocker 11 12 10 0.699
    Beta blocker 67 64 71 0.207
    Diuretic 95 96 95 0.238
    Statin 39 39 38 0.576
    Calcium antagonist 14 13 15 0.645
* for mg/dL divide by 88.4. Abbreviations: ACE: Angiotensin Converting Enzyme; BNP: Brain-type Natriuretic 
Peptide; Bpm: beats per minute; COPD: Chronic Obstructive Pulmonary Disease; CRP: C-Reactive Protein; 
eGFR: estimated Glomerular Filtration Rate; LVEF: Left Ventricular Ejection Fraction; NGAL: Neutrophil Ge-
latinase Associated Lipocalin; NYHA: New York Heart Association functional class.
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Cox proportional hazard analysis was used to assess whether plasma NGAL is a predic-
tor of prognosis. NGAL showed a log-linear functional shape with the response variable 
and was transformed to a log scale. In consecutive models, plasma NGAL was adjusted 
for age and gender, eGFR and finally for the final model, consisting of diastolic blood 
pressure, pulse pressure, history of stroke, myocardial infarction, atrial fibrillation, pe-
ripheral arterial disease, diabetes mellitus, left ventricular ejection fraction, previous hos-
pitalization, serum sodium, BNP and treatment (fully adjusted model).28 For confirma-
tory analysis, BNP was replaced with NT-proBNP. Interactions between plasma NGAL 
and both eGFR and cystatin C were tested. To evaluate predictive utility of plasma NGAL, 
eGFR and cystatin C, areas under the curve (AUCs) of receiver operating characteris-
tics (ROC) curves were calculated. Furthermore, we calculated the incremental value of 
plasma NGAL by means of the integrated discrimination index (IDI) and net reclassifica-
tion index (NRI) for the model of all significant variables, versus this model plus plasma 
NGAL. Cut-off values of mortality were arbitrarily set at 10% and 30%. 
A P value <0.05 was considered statistically significant. Statistical analyses were per-
formed using R Statistics (version 2.13.2) and STATA (version 10, College Station, Texas). 
Results
A total of 562 patients were available for this analysis. These patients did not signifi-
cantly differ from the 461 excluded patients that originally participated in COACH (sup-
plementary table). Mean age was 71±11, 61% were men, 97% were in New York Heart 
Association functional class II or III and 53% had been previously hospitalized due to 
Figure 1. Three years mortality (CKD and non-CKD vs low/high NGAL) - Kaplan-Meier curves showing the 
association between all cause mortality and low/high eGFR (cut-off point 60 ml/min/1.73m2) and low/high 
NGAL (cut-off point 84.62 ng/ml).
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heart failure. Mean baseline eGFR was 54±20 mL/min/1.73m2, mean cystatin C was 11.2 
(7.7–16.2) mg/l and median plasma NGAL was 85 (60-123) ng/ml. 
Table 1 shows the baseline characteristics of the patients according to CKD and non-
CKD. CKD patients were older, were in a higher NYHA class, were less likely to receive 
an ACE inhibitor, had higher levels of cystatin C and NGAL, lower levels of hemoglobin 
(all P < 0.001) and had more co-morbidities. 
Plasma NGAL, eGFR and prognosis
After a follow up of 3 years, 232 (41%) patients died. The mortality in patients with CKD 
was 49% (N = 57/205)  after three year versus 28% (170/347) in the non-CKD-group (HR 
0.48 [0.36-0.65], P < 0.001).
Figure 1 shows the Kaplan  Meier  curves for the occurrence of all-cause mortality. 
Curves are shown for 4 groups (CKD and non-CKD, and high and low NGAL). Within 
the groups of NGAL, there was no difference in mortality between the two CKD groups. 
Overall, higher plasma NGAL levels were independently associated with increased 
mortality. In all consecutive models (plasma NGAL adjusted for age and gender, adjusted 
for eGFR and finally for the fully adjusted model with BNP), higher plasma NGAL levels 
were independently associated with an increased risk of all cause mortality (HR: 1.44 per 
Table 2. Risk models of the predictive value of plasma NGAL, eGFR and cystatine-C in heart failure patients with and without CKD. 
All patients CKD Non-CKD
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
eGFR alone (per SD increase) 1.50 (1.30-1.72) <0.001 1.54 (1.19-1.98) <0.001 1.02 (0.66-1.56) 0.938
eGFR, age-sex-adj. 1.41 (1.21-1.64) <0.001 1.51 (1.17-1.96) 0.002 0.93 (0.60-1.43) 0.726
eGFR, fully adjusted 1.28 (1.10-1.49) 0.001 1.26 (0.94-1.67) 0.121 1.04 (0.62-1.77) 0.858
eGFR, fully adjusted with NGAL 1.04 (0.88-1.24) 0.616 0.87 (0.63-1.21) 0.413 1.00 (0.60-1.67) 0.993
Cyst C alone (per SD increase) 1.15 (1.02-1.30) 0.020 1.04 (0.90-1.19) 0.623 1.24 (0.96-1.62) 0.100
Cyst C, age-sex-adj. 1.11 (0.98-1.26) 0.093 1.04 (0.90-1.20) 0.573 1.18 (0.91-1.55) 0.217
Cyst C, fully adjusted 1.09 (0.96-1.23) 0.208 1.07 (0.92-1.24) 0.406 1.08 (0.82-1.44) 0.572
Cyst C, fully adjusted with NGAL 0.99 (0.87-1.14) 0.937 0.98 (0.84-1.15) 0.836 1.03 (0.77-1.38) 0.844
NGAL alone (per SD increase) 1.61 (1.42-1.83) <0.001 1.48 (1.27-1.72) <0.001 1.62 (1.17-2.23) 0.003
NGAL, age-sex-adj. 1.51 (1.32-1.72) <0.001 1.44 (1.23-1.68) <0.001 1.44 (1.03-2.00) 0.033
NGAL, fully adjusted 1.47 (1.27-1.69) <0.001 1.45 (1.22-1.72) <0.001 1.51 (1.06-2.16) 0.023
NGAL, fully adjusted with eGFR 1.44 (1.22-1.69) <0.001 1.51 (1.24-1.85) <0.001 1.51 (1.06-2.16) 0.024
NGAL, fully adjusted with cyst C 1.47 (1.27-1.70) <0.001 1.45 (1.22-1.74) <0.001 1.50 (1.04-2.16) 0.026
* (per 5ml/min/m2 decrease). Abbreviations: CI: Confidence Interval, cyst C: cystatin C; HR: Hazard Ratio, NGAL: Neutrophil Ge-
latinase Associated Lipocalin. Fully adjusted model: adjusted for age, sex, diastolic blood pressure, pulse pressure, history of stroke, 
myocardial infarction, atrial fibrillation, peripheral arterial disease, diabetes mellitus, left ventricular ejection fraction, previous hos-
pitalization, serum sodium, BNP and treatment allocation.
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SD increase in log NGAL, 95% CI 1.22-1.69, P < 0.001) (Table 2). The prognostic values 
(area under the curve [AUC]) of plasma NGAL and eGFR are shown in table 3. IDI im-
proved significantly adding NGAL to the fully adjusted model (0.029, P < 0.001) whereas 
NRI almost reached the level of statistical significant (0.062, P = 0.054). When BNP was 
replaced with NT-proBNP, results remained consistent.
Divided in CKD and non-CKD, plasma NGAL levels remained significantly associated 
in the consecutive models with three years mortality, in CKD patients and in non-CKD 
patients whereas eGFR was only univariate associated with mortality in CKD patients. 
Furthermore, eGFR was no longer significantly associated with mortality in CKD pa-
tients when plasma NGAL was introduced in the crude, age and sex adjusted and fully 
adjusted model (Table 2).  
Plasma NGAL, cystatin C and prognosis
In accordance with eGFR, we divided cystatin C into two groups. Figure 2 shows the Ka-
plan Meier curves for the occurrence of all-cause mortality (high and low cystatin C, and 
high and low NGAL). Within the groups of NGAL, there was no difference in mortality 
between the two cystatin C groups. 
Again, higher plasma NGAL levels were independently associated with increased mor-
tality, in all consecutive models (adjusted for age, gender and cystatin C, and finally for 
the fully adjusted model with cystatin C) (Table 2). The prognostic value of plasma NGAL 
including cystatin C (measured by AUC) for the total group was higher than the AUC of 
cystatin C without NGAL (table 3). IDI improved significantly adding NGAL to the fully 
adjusted model (0.027, P < 0.001) whereas NRI did not show improvement in discrimi-
Figure 2. Three years mortality (low/high cystatin C vs low/high NGAL) - Kaplan-Meier curves showing the 
association between all cause mortality and low/high cystatin C (cut-off point 11.2 mg/l) and low/high NGAL 
(cut-off point 84.62 ng/ml).
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nation (-0.025, P = 0.409). When BNP was replaced with NT-proBNP, results remained 
consistent. The discrepancy in significance could be explained because IDI can be seen 
as the continuous version if NRI with probability differences used instead of categories.
Divided into high and low cystatin C groups, plasma NGAL levels remained significant-
ly associated in the consecutive models with three years mortality, whereas cystatin C was 
not significantly associated with mortality in both groups. Furthermore, cystatin C was 
no longer significantly associated with mortality in CKD patients when plasma NGAL 
was introduced in the crude, age and sex adjusted and fully adjusted model (Table 2).  
Discussion 
This study shows that plasma NGAL predicts mortality in heart failure patients, both in 
patients with and without chronic kidney disease. Moreover, plasma NGAL is a stronger 
predictor for mortality than the frequently used biomarkers of impaired renal function 
eGFR and cystatin C. 
Plasma NGAL and prognosis
NGAL is a 25 kDa lipocalin-superfamily glycoprotein that is considered to play a role 
in acute kidney injury in a diverse range of settings.16,29 In normal circumstances, only 
small amounts can be found in plasma and urine. However, during and after acute kidney 
injury, NGAL levels rise quickly and massively.30 
Table 3. AUC of models comparing the prognostic value of eGFR and NGAL in heart failure patients with and without CKD.
All patients CKD Non-CKD
eGFR 0.643 (0.596-0.689) 0.596 (0.537-0.654) 0.487 (0.389-0.585)
eGFR, fully adjusted 0.791 (0.753-0.829) 0.786 (0.748-0.824) 0.756 (0.715-0.796)
Cyst C 0.565 (0.517-0.613) 0.515 (0.452-0.573) 0.586 (0.498-0.673)
Cyst C, fully adjusted 0.786 (0.748-0.824) 0.781 (0.743-0.820) 0.758 (0.718-0.798)
NGAL 0.672 (0.627-0.717) 0.636 (0.579-0.693) 0.634 (0.549-0.720)
NGAL, fully adjusted 0.798 (0.761-0.835)
P=0.287 vs eGFR Fam
P=0.099 vs Cystatin C Fam
0.794 (0.756-0.831)
P=0.131 vs eGFR Fam
P=0.021 vs Cystatin C Fam
0.773 (0.734-0.812)
P=0.074 vs eGFR Fam
P=0.109 vs Cystatin C Fam
NGAL, fully adj.+eGFR 0.798 (0.761-0.835)
P=0.877 vs NGAL Fam
0.794 (0.756-0.831)
P=0.593 vs NGAL Fam
0.772 (0.734-0.812)
P=0.275 vs NGAL Fam
NGAL, fully adj.+cyst C 0.799 (0.761-0.836)
P=0.315 vs NGAL Fam
0.794 (0.756-0.832)
P=0.892 vs NGAL Fam
0.773 (0.734-0.812)
P=0.925 vs NGAL Fam
Abbreviations: NGAL: Neutrophil Gelatinase Associated Lipocalin. Fam: Fully adjusted model: adjusted for age, sex, eGFR, 
diastolic blood pressure, pulse pressure, history of stroke, myocardial infarction, atrial fibrillation, peripheral arterial disease, 
diabetes mellitus, left ventricular ejection fraction, previous hospitalization, serum sodium, BNP and treatment allocation.
61Renal tubular damage
In the present study we found that plasma NGAL is independently associated with mor-
tality. This confirms our recent study in which we found that tubular damage in heart fail-
ure was prevalent in chronic heart failure and related to impaired survival, independent 
of GFR and albuminuria.18 In this small study, we were unable to establish the prognostic 
value of urinary NGAL in chronic heart failure. However, in a much larger sub study of 
the GISSI-HF trial, urinary NGAL levels were independently associated with outcome.19 
Bolignano and colleagues found prognostic significance of plasma NGAL levels in 46 
patients with chronic heart failure.20 In three confirmative smaller studies, serum NGAL, 
measured at admission for acute heart failure, predicted death only when NGAL was 
dichotomized by an optimally taken cut off point.21,22 
In the CORONA study, with 1415 patients with chronic heart failure of ischemic eti-
ology, plasma NGAL was an univariate predictor of all-cause mortality, cardiovascular 
death and hospitalization. However, plasma NGAL was no longer a significant predictor 
when adjusted for GFR and NT-proBNP.23 In contrast, Alvelos and colleagues showed 
that plasma NGAL was an independent predictor of increased risk of short term death 
and/or readmission in patients with acute heart failure.22 In the recent GALLANT trail, in 
which plasma NGAL was measured in 186 patients with acute heart failure at discharge, 
plasma NGAL was an even better prognostic indicator compared to BNP.24 
Plasma NGAL in non-CKD patients 
This study shows that plasma NGAL predicts mortality in heart failure patients, even in 
non-CKD patients. Taking into consideration that creatinine is a marker of kidney func-
tion and NGAL is a marker of kidney injury, there are several arguments why tubular 
damage in heart failure patients is associated with prognosis whereas glomerular func-
tion in the mild impaired renal function ranges is not. 
First, in heart failure patients, decreased perfusion may be a key deleterious factor for 
the kidneys. Because the tubulus is more vulnerable to hypoxic damage,4-12 it is possible 
that small declines in renal function result in tubular damage where the renal cortex stays 
intact, maintaining GFR.4,31 Therefore, tubular damage might better reflect a decreased 
perfusion than eGFR.30 
Second, in the acute setting, tubular markers are increased while creatinine is still nor-
mal.14-17 A possible mechanism is that decreased renal perfusion in heart failure leads to 
compensatory glomerular hyperfiltration.32 In fact, renal blood flow can decrease by 30-
40% without apparently affecting functional GFR.31 Notably, tubular markers reflect renal 
injury, instead of renal function. Tubular markers, such as plasma NGAL, are therefore 
likely to be more sensitive than creatinine. 
Third, creatinine levels are dependent of muscle metabolism, weight, age and sex. Al-
though formulas partly overcome this limitation, creatinine is still actively secreted by the 
proximal tubule, especially when GFR is low, making creatinine less useful in extremes 
of true GFR.
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Plasma NGAL compared with eGFR and cystatin C
We show that plasma NGAL is a more powerful predictor of mortality than eGFR. The 
results of the incremental value of plasma NGAL over eGFR are almost similar when 
compared with the results of a more sensitive glomerular marker cystatin C.33,34 While 
eGFR is regularly used in daily practice, cystatin C can be seen as a more accurate reflec-
tion of glomerular function. In acute settings, creatinine is known to be a slower mark-
er.33,34 Creatinin based formulas are less accurate in extremes of true eGFR27 and this is 
one of the factors why cystatin C is superior to creatinine.35-38 Moreover, cystatin C is 
less dependent on body mass, decreased muscle mass and cachexia, which are present in 
patients with chronic heart failure.39-42 
Nevertheless, even when related to and adjusted for cystatin C, plasma NGAL remained 
to have a better prognostic value. This might indicate that in heart failure patients, tu-
bular damage might better reflect an impaired hemodynamic status as compared with 
glomerular function.
Limitations 
Recognizing the importance of renal biomarkers in heart failure for improving risk 
stratification, there are several concerns in analyzing different biomarkers. It would be 
best to approach the accuracy of risk prediction with a multi-marker approach.
Primary renal disease was not excluded at baseline in this study. Therefore, the observed 
relationships could have been affected by underlying renal disease, where associations be-
tween tubular damage, glomerular function and outcome can be different. Larger studies 
are required to confirm our results, preferably with a specific intervention to investigate 
effects rather than associations. Also, we do not have information on cause of death.
Kidney disease may not only be identified by low GFR or tubular damage. Unfortu-
nately we do not have sufficient data on albuminuria in the COACH-cohort.43,44
We assessed plasma NGAL, rather than urinary NGAL, which may be more affected 
by specific confounders such as bacterial infection, presence of cancer or COPD and in-
flammation,30 although C-reactive protein was not correlated with plasma NGAL in the 
present study. Plasma levels of NGAL still increase markedly (up to 16-fold) in the setting 
of renal tubular injury. Plasma NGAL also has the advantage of easy collection, because 
plasma is already collected in the clinical setting.45
Conclusions
The present study shows the incremental prognostic value of plasma NGAL in heart 
failure patients with and without renal dysfunction. Moreover, plasma NGAL is a strong-
er predictor for mortality than frequently used biomarkers of chronic kidney disease.
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Abstract
Background
Contradictory results have been reported on the effects of nesiritide on renal function in 
patients with acute decompensated heart failure (ADHF). We studied effects of nesiritide 
on renal function during hospitalization for ADHF.
Methods
A total of 7141 patients were randomized to receive either nesiritide or placebo. Baseline 
and discharge creatinine and blood urea nitrogen (BUN) measurements were available in 
4708 patients. Worsening renal function was defined as an increase of serum creatinine 
>0.3 mg/dL and >25% at any time during hospitalization. 
Results
Median (25th–75th percentile) baseline creatinine was 1.2 (1.0–1.6) mg/dL and median 
baseline BUN was 25 (18–38) mmol/L. Changes in both serum creatinine and BUN were 
similar in nesiritide-treated (p=0.20) and placebo-treated (p=0.41) patients. In a multi-
variate model, independent predictors of an increase in serum creatinine were a lower 
baseline BUN, higher systolic blood pressure, prior weight gain, and lower baseline po-
tassium (all p<0.0001). The frequency of worsening renal function during hospitalization 
was similar in the nesiritide and placebo group (14.1% and 12.8%, respectively; odds ratio 
with nesiritide 1.12 [0.95–1.32], p=0.19) and was not associated with death or rehospi-
talization at 30 days. However, both baseline  and discharge creatinine were associated 
with death or rehospitalization (both p<0.0001).
Conclusions
Nesiritide did not affect renal function in patients with ADHF. Both baseline and dis-




Nesiritide is recombinant B-type natriuretic peptide (BNP)1-4 approved for use in pa-
tients with acute heart failure, due to its ability to reduce pulmonary-capillary wedge 
pressure and improve dyspnea.3,5 Yet after approval, it was suggested that nesiritide might 
cause renal toxicity and increase mortality. Specifically, in a meta-analysis of five rand-
omized studies with 1269 acute heart failure patients compared with placebo, intravenous 
nesiritide increased the rate of worsening renal function by 50%, although confidence 
intervals around this estimate were wide.7,8 These concerns led to a marked decrease in 
the use of this nesiritide.6
The Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Fail-
ure (ASCEND-HF) was conducted to re-evaluate the efficacy and safety of nesiritide, 
compared with placebo added to standard-of-care in 7144 acute decompensated heart 
failure patients. Overall, compared with placebo, nesiritide did not improve (or wors-
en) clinical outcomes and nesiritide did not increase the risk of worsening renal func-
tion (pre-defined as more than a 25% decrease in estimated glomerular filtration rate 
[eGFR]).9
The present analysis was a retrospective analysis of ASCEND-HF, in which we exam-
ined the detailed effects of nesiritide on renal function, clinical predictors on changes in 
creatinine and blood urea nitrogen (BUN) during hospitalization, and the relationship 
between changes in renal function and outcomes.  
Methods
ASCEND-HF was a randomized, double blind, placebo-controlled trial of nesiritide in 
addition to standard of care.10 The trial was conducted from May 2007 through August 
2010 at 398 international centers. Patients were included if they were hospitalized for 
heart failure occurring within 24 hours before they received their first intravenous treat-
ment for heart failure, or if they had received a diagnosis of acute decompensated heart 
failure (ADHF) less than 48 hours after hospitalization for another cause, and underwent 
randomization within 24 hours after intravenous treatment. Patients were excluded if 
they had a high-risk of hypotension (systolic pressure <100 mm Hg or 110 mm Hg with 
the use of intravenous nitroglycerin), other contraindications for vasodilators, persistent 
uncontrolled hypertension, normal levels of BNP or N-terminal (NT-) pro-BNP, chronic 
or intermittent renal support therapy (hemodialysis, ultrafiltration, or peritoneal dialy-
sis), or clinically significant anaemia.10 Eligible patients were randomly assigned in a 1:1 
ratio to receive nesiritide or placebo, in addition to standard therapy. After a recom-
mended (but optional) intravenous bolus of nesiritide, at a dose of 2 μg per kilogram, 
nesiritide was administered as a continuous infusion of 0.010 μg per kilogram per minute 
for 24 hours or more for up to 7 days.
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The ASCEND-HF study was approved by each participating center’s ethics committee 
or institutional review board, and all participants were provided written informed con-
sent (ClinicalTrials.gov number, NCT00475852).
Patients for Analyses
A total of 7141 patients underwent randomization; of these, 7007 (98%) received the 
study drug and were included in the modified intention-to-treat analysis. The study 
groups were well-balanced and similar to the intention-to-treat group.9 Our retrospective 
analysis of ASCEND-HF focuses on the 4708 patients who had a baseline and at least one 
follow-up creatinine measurement available for review.
Worsening Renal Function
Worsening renal function was defined as an increase of serum creatinine >0.3 g/dL (26.5 
µmol/L) in combination with >25% increase in creatinine during hospitalization. Creati-
nine was measured at baseline, after 24 hours, at the end of treatment and at discharge. By 
measuring worsening renal function by relative and absolute rates we accounted for the 
exponential relationship between serum creatinine and eGFR.11,12 
Endpoints
The primary endpoint of interest in this study is the composite of rehospitalization 
for heart failure and death from any cause within 30 days post-event. Other endpoints 
of interest include the separate outcomes of rehospitalization for heart failure or death 
from any cause within 30 days, and death from any cause within 180 days. The following 
criteria were required for hospitalization events to be classified as due to heart failure: 
typical clinical manifestations of worsening heart failure and the addition of (or increase 
in) treatment specifically for worsening heart failure with an intravenous pharmacologic 
agent, or mechanical or surgical intervention or ultrafiltration, hemofiltration, or dialysis 
specifically for management of persistent or worsening heart failure.
Statistical Analyses 
Change in creatinine was defined as the change from baseline to discharge; in Table 1, 
the change is displayed in quintiles. Presenting factors, baseline medications, and medical 
history information is reported as counts and frequencies for discrete factors and either 
the mean with standard deviation or 50th, 25th, and 75th percentiles. A Wilcoxon rank-
sum test was performed for continuous factors and a chi-square test was performed for 
binary measurements.  
Regression modeling was generated to assess the pre-specified baseline factors on 
change in creatinine. In order to verify that modeling assumptions were met, plots were 
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generated to view the residuals of each independent predictor and outcome. The BUN, 
BNP, and NT-proBNP were all modeled using a log transformation. A proc univariate 
test for normality was also generated to ensure modeling assumptions were met.  The 
stepwise procedure was selected using a p-value of 0.05 for entry and to stay in the model. 
Interaction between treatment and baseline factors were reviewed. An additional out-
come of interest is mortality or heart failure re-hospitalization by 30 days and mortality 
within 180 days of randomization. SAS version 9.2 (SAS Institute, Cary, North Carolina, 
USA) was used for all analyses.
Results
The clinical characteristics of 4708 patients who were included in the present study 
did not significantly differ from the 2433 patients who were excluded, due to missing 
creatinine serial data (data not shown). Table 1 shows the baseline characteristics of the 
included population. In short, median age was 65 ± 14 year, and 34% were female. Ne-
siritide treatment was given to 50% of the included patients. A history of hypertension 
was present in 72% of patients and 35% had a history of myocardial infarction. Median 
weight was 78 (64–95) kg with a median change in weight of -2.3 (-5.0 – -0.6) kg during 
hospitalization. Loop diuretics were administered in 82% of all patients within the first 
24 hours. 
Change in Renal Function
Median creatinine concentration increased from 1.2 (1.0–1.6) mg/dL at baseline to a 
maximum of 1.4 (1.1–1.9) mg/dL, during hospitalization. Median BUN concentration 
increased from 25 (18–38) mmol/L at baseline to a maximum of 33 (23–50) mmol/L, 
during hospitalization. The change in both serum creatinine and BUN was similar in 
nesiritide- and placebo-treated patients (p=0.20 and p=0.41, respectively) as shown in 
Figure 1 and supported by the cumulative distribution curves shown in figure 2.
In Table 1, patients were grouped by quintiles of serum creatinine change between base-
line and discharge. Patients with the greatest increase in creatinine were older, more often 
female, more often had diabetes, had higher left ventricular ejection fraction (LVEF), 
higher NT-proBNP levels (although the highest values were seen in the first quintile), a 
higher baseline systolic blood pressure, and more cardiovascular comorbidities includ-
ing diabetes. Patients in the highest quintile more often received loop diuretics within 
the first 24 hours, had a higher weight at baseline, and more decrease in weight during 
hospitalization. 
Worsening renal function at any time from randomization through discharge occurred 
in 13.4% of the patients and the frequency was similar in the nesiritide and placebo 
groups (14.1% and 12.8%, respectively; odds ratio with nesiritide 1.12; 95% confidence 
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interval, 0.95–1.32, p=0.19), regardless of the degree of baseline renal insufficiency (OR 
1.01 [0.79-1.28, p=0.955 in patients with baseline eGFR <60 ml/min/1.73m2, and OR 1.24 
[0.98-1.57], p=0.076 in patients with baseline eGFR ≥60 ml/min/1.73m2).
Using a multivariable stepwise model, we defined characteristics that were related to 
changes in creatinine (Table 2). In summary, a lower baseline BUN (log β -0.091, p<0.0001), 
a higher systolic blood pressure (β 0.002 in standard deviation [SD], p<0.0001), a low-
er diastolic blood pressure (β -0.002, p<0.0001), a lower baseline potassium (β -0.040, 
p<0.0001), and prior weight gain (β 0.039, p<0.0001), were all significantly related to an 
increase in serum creatinine. Treatment with nesiritide did not have a significant relation 
to a change in creatinine (β 0.001, p=0.89).
Table 2. Characteristics Independently Related to Changes in Creatinine.
Parameter Estimate Standard Error t-value Pr >|t| P-value
Intercept 0.32977 0.05367 6.14 <0.0001 0.0212
Planned treatment 0.00127 0.00939 0.14 0.8921 0.0017
Log BUN -0.09123 0.00874 -10.44 <0.0001 0.0004
Baseline SBP (mmHg) 0.00230 0.00028 8.15 <0.0001 0.0819
Baseline DBP (mmHg) -0.00183 0.00041 -4.49 <0.0001 0.3873
Potassium (mmol/L) -0.04013 0.00818 -4.90 <0.0001 0.9894
Prior weight gain 0.03898 0.00992 3.93 <0.0001 0.2412
All abbreviations can be found in Table 1. 
Figure 1a. Patients Randomized to Either Nesiritide or Placebo. This figure displays the changes in (a) serial 
creatinine levels.
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Table 3. The Prognostic Value of Serum Creatinine at Different Time Points for 30-day Mortality.
Measure of Creatinine Univariate 
Hazard Ratio
Chi-square p-value
Baseline creatinine (per 1.5 fold increase) 1.487 61.31 <0.001
Discharge creatinine (per 1.5 fold increase) 1.533 40.88 <0.001
Change in creatinine (per 0.3 increase) 1.090   1.60   0.206
Table 4. The Prognostic Value of Serum Creatinine at Different Time Points for 30-day Death or Re-
hospitalization.
Measure of Creatinine Univariate 
Hazard Ratio
Chi-square p-value
Baseline creatinine (per 1.5 fold increase) 1.357 117.95 <0.001
Discharge creatinine (per 1.5 fold increase) 1.417 108.13 <0.001
Change in creatinine (per 0.3 increase) 1.001     0.02   0.902
Figure 1b. Patients Randomized to Either Nesiritide or Placebo. This figure displays the changes in (b) BUN 
levels in patients randomized to either nesiritide or placebo. BUN indicates blood urea nitrogen.
Predictive Value of Creatinine in relation to Clinical Outcomes
The prognostic value of serum creatinine and change in serum creatinine at different 
time points is shown in Tables 3 and 4. Table 3 shows that creatinine at baseline (Chi-
square 61.3, p<0.0001) and at discharge (Chi-square 40.9, p<0.0001) both had a strong 
association with 30-day mortality. Creatinine at baseline and at discharge also had a 
strong association with the combined endpoint of 30-day mortality or re-hospitalization 
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(Chi-square 118.0 and 108.1, both p<0.0001). Conversely, increase in creatinine between 
baseline and discharge had no association with either 30-day mortality (Chi-square 1.6, 
p=0.21) or the combined endpoint (Chi-square 0.02, p=0.90).
Overall, worsening renal function was not associated with the combined endpoint of 
mortality and heart failure hospitalization within 30 days (hazard ratio [HR] 1.12 [0.81–
1.50], p=0.52), nor with the separate endpoint of death within 30 days (HR 0.96 [0.51–
1.82], p=0.90), nor with heart failure hospitalization within 30 days (HR 1.16 [0.83–1.62], 
p=0.40).
Discussion
In the present renal retrospective analysis of the ASCEND-HF trial, we found that ne-
siritide did not have any effect on changes in creatinine or BUN during hospitalization 
in patients with ADHF. Baseline and discharge renal function, but not worsening renal 
function, were associated with 30 day death and death or  re-hospitalization. 
 
Worsening Renal Function
Renal dysfunction is prevalent in patients with both chronic and acute heart failure, 
and may influence patients’ treatments and outcomes.13 It is known that 20-40% of pa-
tients with acute heart failure have an increase in creatinine, which is generally defined as 
Figure 2a. Cumulative Distribution Curve. This figure displays the cumulative distribution curves of both ne-
siritide and placebo on (a) creatinine at end of treatment.
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worsening renal function.13 We also found that the prevalence of diabetes was higher in 
patients with more worsening renal function, confirming previous studies.27,28
In our study, we found that baseline renal function was mildly impaired and decreased 
further during hospitalization. Predictors of a decline in renal function (measured us-
ing creatinine on a continuous scale) included higher systolic and lower diastolic blood 
pressure, lower potassium levels, more prior weight gain, and lower BUN levels; thereby 
confirming previous studies.12,14-16
Nesiritide
In a meta-analysis of five randomized studies that included 1269 ADHF patients, the fre-
quency of worsening renal function was found to be 50% more prevalent in the nesiritide 
group.7 Therefore, the neutral effects of nesiritide on renal function in the present study 
is markedly different from the meta-analysis. There are several potential explanations for 
this difference. First, it should be noted that from 3 studies, data cannot be obtained, since 
they have not been published.30 In the remaining 2 studies, nesiritide was not compared 
with placebo, as in ASCEND-HF, but with either dobutamine29 or nitroglycerin,3 and we 
cannot exclude the possibility that these agents may have had a positive effect on renal 
function. Second, ASCEND-HF excluded patients with high risk of hypotension (systolic 
pressure <100 mm Hg or 110 mm Hg with the use of intravenous nitroglycerin), while the 
VMAC and Precedent had less strict exclusion criteria for hypotension (90 mm Hg and 
Figure 2b. Cumulative Distribution Curve. This figure displays the cumulative distribution curves of both ne-
siritide and placebo on (b) discharge/day 10.
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85 mm Hg respectively).  Third, in the meta-analysis, the confidence intervals around the 
estimate were wide, suggesting that larger studies were needed. Also, after publication of 
the meta-analysis data from another study suggested that nesiritide might even improve 
renal function.17 With 7141 patients, ASCEND-HF had definitive power to demonstrate 
a meaningful difference in renal function between placebo and nesiritide and no differ-
ence was found.9 
The present retrospective analysis of ASCEND-HF presents a more detailed report on 
the associations between nesiritide and other clinical predictors on changes in creatinine 
and blood urea nitrogen (BUN) during hospitalization, as well as the drug’s association 
with clinical outcomes. We demonstrated that there was not a significant relationship 
between nesiritide and change in renal function (measured by creatinine or BUN) when 
corrected for clinical characteristics and other laboratory measurements.
Since hypotension is related to worsening renal function in acute decompensated heart 
failure,18 there was some concern that patients with hypotension had a higher rate of 
renal impairment compared to those without hypotension. We found this concern to be 
true in the overall group, as well as within each treatment group. Importantly, the overall 
relative risk of increased serum creatinine was the same within both treatment groups. So 
despite there being some correlation between hypotension and renal dysfunction, there 
was no evidence of a stronger correlation when using nesiritide.
Outcomes
We assessed the association between baseline and discharge creatinine and short-term 
outcomes, as well as the change in creatinine between baseline and discharge both as a 
continuous measure and as a categorical one (looking at “worsening renal function”). 
Both serum creatinine at baseline and serum creatinine at discharge had a strong asso-
ciation with both 30-day mortality and with the combined endpoint of 30-day mortality 
or re-hospitalization. Both continuous change and worsening renal function were not 
associated with short-term outcomes. 
In contrast to other studies, we did not find worsening renal function to be associated 
with worse short-term outcomes in patients with ADHF.11,12,19-24 There are several poten-
tial explanations for this disparity. First, there could be a measurement bias. Most studies 
do not measure creatinine routinely, so in those that did, there was probably a reason, 
which perhaps means that these patients were more likely to have worsening of symp-
toms, non-response to diuretics, related to clinical outcomes. The theory of measure-
ment bias is supported by a recent study comprised of 599 patients who had their serum 
creatinine levels routinely measured.25 The authors of this study concluded that worsen-
ing renal function is not an independent predictor of outcomes in patients with ADHF. 
Interestingly, they found that worsening renal function was prognostic in patients with 
persistent signs of congestion, suggesting a differential effect of worsening renal function. 
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According with our findings, the prospective randomized DOSE-trial found that pa-
tients that were given high dose of diuretics had greater diuresis and more favorable out-
comes, although transient worsening of renal function occurred.26 This might suggests 
that an increase in creatinine caused by a good diuretic response might be related to a 
better outcome. 
Limitations 
The present study has several limitations. First, our study has limitations due to the ret-
rospective nature of this analysis. Second, our study has a possible selection bias inherent 
in clinical trial populations. For instance, our study population largely consists of North 
American patients, possibly limiting the generalizability of our findings.
Third, 2433 patients did not have serial creatinine values, which could have potentially 
biased the finding that worsening renal function did not predict patient outcomes. For 
example, patients who lacked serial creatinine values could have developed worsening 
renal function in-hospital and died before their serial creatinine was measured. Never-
theless, due to the design of ASCEND-HF, this study is more likely to have missing data 
because of less specific reasons, whereas other studies are more likely to have missing 
values because patients had no clinical suspicion to have worsening renal function or 
worse clinical outcomes.
Conclusions
In the present renal retrospective analysis of ASCEND-HF, examining 4708 patients 
who were hospitalized with ADHF, nesiritide did not affect renal function. In addition, 
both baseline and discharge renal dysfunction was associated with a higher 30 day mor-
tality and re-hospitalization, while the change in renal function and/or worsening renal 
function was not.
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Abstract
Background
We studied the relation between liver function abnormalities and hemodynamic profile 
in patients with heart failure (HF).
Methods
In 323 HF patients, liver function was determined by aspartate and alanine aminotrans-
ferase (AST, ALT), alkaline phosphatase, g-glutamyl transpeptidase (GGT), lactate de-
hydrogenase, and direct and total bilirubin (Bili dir, Bili tot). Central venous pressure 
(CVP) and cardiac index (CI) were determined invasively. Follow-up consisted of time 
to all-cause mortality. 
Results
Mean age was 53 ± 15 years, and 60% were male. In multivariable analysis, all liver func-
tion tests related to CVP, but higher CVP was predominantly related to GGT (r = 0.336, P 
< 0.001) and Bili dir (r = 0.370, P < 0.001). Only elevated AST (r = -0.177, P < 0.01), ALT 
(r = -0.130, P < 0.05), and Bili tot (r = -0.158, P < 0.01) were associated with both low CI 
and elevated CVP. The prognostic value of abnormal liver function tests was related to 
their interaction with CI and CVP.
Conclusions
Elevated liver function tests mainly indicate higher CVP, whereas only the presence of 
elevated AST, ALT, or Bili dir may indicate a low CI. The absence of prognostic infor-
mation in the presence of invasive hemodynamic measurements suggests that abnormal 
liver function tests in HF reflect a poor hemodynamic status.
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Introduction
Despite initiation of new therapies, both the short- and long-term mortality rate of pa-
tients with heart failure is still high.1,2 This may be at least partly attributable to frequently 
present comorbidities.3-5
Heart failure itself is characterized by impaired organ perfusion resulting from both 
forward failure and increased central venous pressure (backward failure). We recently 
showed that both forward and backward failure are the most important determinants of 
renal dysfunction in heart failure.6,7 Liver function abnormalities are frequently found in 
patients with heart failure and are related to a poor outcome.8-15 Individual small reports 
have highlighted the importance of either high central venous pressure or reduced he-
patic perfusion.12,16-18 However, the relative contribution of reduced perfusion (forward 
failure) or venous congestion (backward failure) in causing alterations in specific markers 
of liver function has not been established.
We studied the relation between liver function abnormalities and forward and back-
ward failure in patients with heart failure.
Methods
Retrospective chart review was done to analyze characteristics of all patients that under-
went right heart catheterization between January 1, 1989, and December 31, 2006, at the 
University Medical Center Groningen, The Netherlands. For each patient, date of birth, 
gender, weight, and height were collected. Comorbid conditions, medical history, labo-
ratory values including serum creatinine and hemoglobin levels, and use of medication 
were also collected. Left ventricular ejection fraction (LVEF) measured within a 6-month 
interval before or after catheterization was recorded. For the present analysis, all patients 
with a diagnosis of clinical heart failure at the time of right heart catheterization were 
included.
Heart catheterization
Hemodynamic variables obtained during catheterization included systolic blood pres-
sure (SBP, mm Hg), diastolic blood pressure (DBP, mm Hg), cardiac output (thermodilu-
tion, l/min), and right atrial pressure as indicator of central venous pressure (CVP, mm 
Hg). Cardiac index (l/min/m2) was determined as cardiac output divided by the body 
surface area. Body surface area was calculated as 0.007184 · weight 0.425 · length 0.725. Body 
mass index was calculated as weight/length2. Measurements obtained from cardiac cath-
eterization were obtained from the patient during a resting state.
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Liver function testing
Laboratory measurements were extracted from samples drawn within 3 days before 
catheterization. Liver function tests that were extracted included aspartate aminotrans-
ferase (AST, upper limit of normal [ULN] 40 U/l), alanine aminotransferase (ALT, ULN 
30 U/l), alkaline phosphatase (ALP, ULN 120 U/l), g-glutamyl transpeptidase (GGT, 
ULN 65 U/l), lactate dehydrogenase (LDH, ULN 235 U/l), direct bilirubin (Bili dir, ULN 
5 mmol/l), and total bilirubin (Bili tot, ULN 26 mmol/l). Abnormal liver function tests 
were defined as values above the upper limit of normal. To account for confounding by 
drug-induced liver injury, we investigated medication use of all patients that showed ei-
ther a hepatocellular profile (ALT > 3 · ULN), a cholestatic profile (ALP > 2 · ULN, ALT/
ALP < 2) or a mixed profile (ALP and ALT > ULN) of liver injury, according to Chang et 
al.19 In addition, we also screened patients with liver function tests values higher than 5 
times ULN. After exclusion of subjects on possible hepatotoxic medication, a history of 
hepatitis or substance abuse, and missing laboratory samples within 3 days before right 
heart catheterization, 323 heart failure patients were available for the present analysis.
Mortality data
Survival status was determined using the electronic patient registration database of the 
University Medical Center Groningen. Follow up started directly after right heart cath-
eterization. The end point of interest was death from any cause.
Statistical analysis
Data are given as mean 6 standard deviation when normally distributed, as median 
and interquartile range when skewed distributed, and as frequencies and percentages for 
categorical variables. Differences between baseline variables were evaluated by means 
Student t-test, the Kruskal-Wallis test, and Chi-square≤ or Fisher exact tests, when ap-
propriate. CI and CVP were ranked to arbitrary high versus low values (CI ≤ / > 2.5 l/
min/m2 and CVP ≤ / > 8 mm Hg), corresponding to the lower limit of normal values of CI 
and higher upper limit of normal values of CVP, corresponding to hemodynamic profiles 
in heart failure.20 Accordingly, we stratified patients to 4 different hemodynamic profiles. 
1. Patients with a normal / high cardiac index (> 2.5 l/min/m2) and normal / low CVP 
(≤ 8 mm Hg)
2. Patients with a normal / high cardiac index (> 2.5 l/min/m2) and a high CVP (> 8 
mm Hg)
3. Patients with a low cardiac index (≤ 2.5 l/min/m2) and a normal / low CVP (≤ 8 
mm Hg)
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Initial linear regression analyses for liver function parameters were performed using 
partial correlation coefficients, adjusted for age and gender. Afterwards, multivariable re-
gression analysis included CI, CVP, age, and gender into the model. Interactions between 
CI and CVP were modeled and a P value < 0.1 was deemed as a significant interaction. 
To account for possible confounding by body mass index, a history of diabetes, SBP, and 
DBP, these factors were introduced as covariates in a secondary multivariable model. We 
used a Cox proportional hazards model to estimate hazard ratios for all-cause mortality 
with 95% CI. Multivariable models were constructed in the following way: liver function 
tests with noninvasive variable, liver function test with invasive measurements (CVP and 
CI), and a stepwise multivariable model. A P value < 0.05 was considered statistically 
significant. Statistical analyses were performed using SPSS, Chicago, version 12.0, and 
STATA, College Station, TX, version 9.0.
Results
Baseline characteristics of the patient population are shown in Table 1. Age was 53 ± 15 
years, and 60% were male. Direct bilirubin (62%) and LDH (65%) were often abnormal 
in this heart failure patient cohort, whereas AST (18%) or ALT (43%) abnormalities were 
Figure 1. Percentages of abnormal liver function tests in patients with heart failure. ALP = alkaline phosphatase; 
AST = aspartate aminotransferase; ALT = alanine aminotransferase; GGT = g-glutamyl transpeptidase; LDH = 
lactate dehydrogenase; bili dir = direct bilirubin; bili tot = total bilirubin.
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much less common (Figure 1). When stratified for different hemodynamic profiles, there 
were marked differences in these 4 groups with respect to liver function tests. In general, 
patients with lower CI tended to have significantly higher values of liver function pa-
rameters, whereas a similar, but less pronounced pattern was observed in patients with 
higher CVP, but relatively normal CI levels. In patients with both high CVP and low CI, 
the highest values of most liver function parameters were observed.
Liver function tests and hemodynamic parameters
Table 2 summarizes linear regression analysis, adjusted for age and gender and for all 
liver function tests, highlighting the association with CVP and CI. All liver function tests 
showed a significant relationship with CVP and an inverse relationship with CI. Compar-
ing CVP and CI, the relationship with CVP was stronger for all liver function tests com-
pared with CI. We found significant interactions between CVP and CI on the relationship 
with total bilirubin, AST, and ALT, but with not direct bilirubin, LDH, ALP, or GGT 
Figure 2. Prevalence of abnormal liver function tests in subgroups of CI and CVP: interaction between CI and 
CVP. (A) Total bilirubin, (B) AST, (C) ALT. CI = cardiac index; CVP = central venous pressure; AST = aspartate 
aminotransferase; ALT = alanine aminotransferase.

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(Table 3). Figure 2 shows the percentages of abnormal liver function tests when both CVP 
and CI were ranked to high versus low, visualizing the significant interaction between 
CVP and CI on these liver function tests. Most liver function tests showed an increase in 
percentages of abnormal values with decreasing CI and increasing CVP. AST and ALT 
were particularly increased when CI was low, and GGT was particularly increased when 
CVP was high. Bilirubin tests were increased both with elevated CVP and low CI. In 
multivariable analysis, CVP remained significantly associated with all liver function tests 
(Table 3). In contrast, CI remained only significantly associated with AST, ALT, and total 
bilirubin. In a second multivariable analysis, which included body mass index, SBP, DBP, 
and a history of diabetes as covariates, the associations between CI, CVP, and liver func-
tion tests were unaffected (coefficients not shown).
Liver function tests and prognosis
During a median follow-up time of 7.9 (4.1-11.8) years, a total of 122 (36%) patients 
died. Table 4 summarizes the relationship between the individual liver function tests and 
prognosis. In univariate analysis, GGT, ALP, AST, and LDH levels were significant pre-
dictors of all-cause mortality. In addition, both CVP (HR 1.03 per mm Hg [1.00-1.06], 
P < 0.05) and CI (HR 0.61 per l/min/m2 [0.45-0.83], P = .0016) significantly determined 
Table 5. Different hemodynamic profiles and expected abnormal levels of liver function tests.
Low CVP High CVP
GGT = GGT ↑ ↑
ALP = ALP ↑
Bili tot = Bili tot ↑
High CI Bili dir = Bili dir ↑
AST = AST ↑
ALT = ALT ↑
LDH = LDH ↑
GGT = GGT ↑ ↑
ALP = ALP ↑
Bili tot ↑ Bili tot ↑ ↑
Low CI Bili dir = Bili dir ↑ ↑
AST ↑ ↑ AST ↑ ↑
ALT ↑ ALT ↑ ↑
LDH = LDH ↑
CI = cardiac index; CVP = central venous pressure; ALP = alkaline phosphatase; AST = aspartate 
aminotransferase; ALT = alanine aminotransferase; GGT = g-glutamyl transpeptidase; 
LDH = lactate dehydrogenase; Bili dir = direct bilirubin; Bili tot = total bilirubin.
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prognosis. After adjustment for noninvasive covariates, AST and LDH remained signifi-
cantly associated with impaired survival, whereas ALT showed a trend with survival (P = 
0.070). However, after adjustment for hemodynamic factors (CI and CVP), none of the 
liver function tests remained associated with impaired survival, which was attributable to 
inclusion of both parameters (CI and CVP) into the model.
Discussion
In the present study, we show that liver function abnormalities are frequently observed 
in patients with heart failure-in particular, high levels of direct bilirubin, LDH, and GGT. 
Most parameters of liver function were predominantly related to CVP, whereas only AST, 
ALT, and total bilirubin were also related to a reduced CI. CVP and CI showed a signifi-
cant interaction on the association with liver function parameters, indicating a mutually 
mediating role of both parameters on the relationship of each individual parameter with 
liver function. Finally, levels of GGT, ALP, and especially AST and LDH were predictors 
of all-cause mortality, but not independent of CI and CVP.
Prevalence and Pathophysiology of Liver Function Abnormalities in Heart Failure
The presence of liver function abnormalities in heart failure has long been recog-
nized.11,14 In our analysis, the prevalence of liver function abnormalities ranged from as 
little as 15% to as much as 65%, depending on definition and type of liver function ab-
normality. We observed similar per- centages of abnormal levels GGT, bilirubin levels, 
and a higher percentage of abnormal levels of ALT and AST compared with a study by 
Lau et al.18 In comparison with a recent substudy of the Candesartan in Heart Failure: 
Assessment of Reduction in Mortality and Morbidity (CHARM) trials we found similar 
percentages of abnormal levels of ALP, but much higher percentages of abnormal levels 
of other liver function tests.8
The pathophysiology of liver failure in heart failure patients has been attributed to either 
venous congestion leading to hepatic congestion or reduced cardiac output leading to 
hepatic hypoxic injury.12,14,18 Liver failure in heart failure includes necrosis in the central 
zone of hepatic lobules resulting from direct compression and congestion.13 Interestingly, 
low perfusion seems to be less important because oxygen consumption can easily be in-
creased when hepatic blood flow is decreased,12 because 70% of the blood supply of the 
liver is dependent of the portal system, whereas only 30% is delivered by the hepatic 
artery.21 A nonhemodynamic factor that may be related to liver failure is poor nutrition 
state of heart failure patients, leading to fatty liver and fibrosis.22
The present study offers more insight in the association of a combination of congestion 
and reduced perfusion with the presence of liver function abnormalities. Historically, 
increased levels of AST and ALT in heart failure have been attributed to hepatocellu-
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lar damage from decreased perfusion, whereas especially increased bilirubin levels, high 
ALP levels, and low ALT/ALP ratio in heart failure have been associated with cholestatic 
liver injury from an increased CVP. Kubo et al have shown that with increasingly severe 
heart failure, the occurrence of liver function abnormalities increases.17 This seemed to 
be parallel to an increase in CVP and decrease in cardiac output, although no interaction 
or multivariable analysis was performed. Our present univariate analyses are consistent 
with their findings, resulting in moderate relationships between CVP and liver function 
tests, and even weaker relationships with CI. Interestingly however, to the best of our 
knowledge, no other data are available in heart failure patients to support this generally 
accepted concept. We found significant interactions between CVP and CI on the relation-
ship with liver function tests. Essentially, all levels of liver function parameters increased 
with decreasing CI and increasing CVP, except for ALT and AST. Both ALT and AST only 
showed elevations when CI was reduced. Because these abnormalities often coexist, this 
finding seems to be a reflection of the pathophysiology of liver function abnormalities in 
heart failure being a combination of congestion and reduced cardiac output. A similar 
analysis for total bilirubin levels was carried out by Shinagawa et al in 183 acute heart 
failure patients.15 Their analysis showed that especially the combination of congestion 
and reduced perfusion led to elevated total bilirubin levels, consistent with our present 
findings. Unfortunately, no data on other parameters of liver dysfunction were shown. 
Lau et al showed that, especially, GGT and bilirubin levels were increased in patients 
with elevated CVP.18 Together with our findings, this suggest that elevations in GGT, 
ALP, LDH, and bilirubin levels are dependent of both reduced perfusion and congestion, 
whereas AST and ALT levels are mainly determined by reduced hepatic perfusion. This 
suggests that low hepatic perfusion in heart failure mainly predisposes to hepatocellular 
liver injury (high AST and ALT), whereas cholestatic liver injury is primarily observed 
when CVP is particularly high (high bilirubins, GGT, ALP). Additionally, our findings 
may help to identify patients in different hemodynamic profiles, according to abnormal 
values, or combination of abnormal values of different liver function test (Table 5).
Prognosis
Several reports have addressed the prognostic importance of liver function abnormali-
ties in the setting of heart failure. Batin et al showed that individual abnormal liver func-
tion tests were related to increased mortality, including bilirubin and AST.9 Shinagawa 
also emphasized the importance of elevated total bilirubin levels, whereas direct bilirubin, 
ALP, and GGT were also related to cardiac events.15 In a recent report, Allen et al reported 
independent prognostic information of bilirubin in the CHARM study population, but 
in our present study, we were unable to find a relationship between bilirubin levels and 
mortality.8 We did, however, find that GGT, ALP, LDH, and AST were significantly related 
to mortality in univariate analysis. Even after correction for easily obtainable, noninva-
sive covariates, AST and LDH remained significant predictors of prognosis. Interestingly, 
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after adjustment for hemodynamic derangement (CVP and CI), none of these liver func-
tion tests remained associated with reduced survival.
This observation seems to indicate that the severity of liver function abnormalities is 
related to the type of liver function test and the relative contributions of CVP and CI. The 
prognostic importance of these abnormalities seems to be more a reflection of the poor 
hemodynamic status of these patients, instead of underlying secondary hepatic injury.
Limitations
This is a retrospective analysis of a selected patient population, which includes patients 
who were identified in the early 1990s. Considering the improvement in medical therapy 
in patients with heart failure in recent years, our heart failure population may have a 
higher prevalence of liver function abnormalities compared with the general heart failure 
population now. We carried out multiple comparisons in a limited set of patients, which 
increases the change of finding significant relationships. Our results should therefore be 
confirmed in other studies. Furthermore, changes in liver function abnormalities were 
not assessed and we cannot assess whether the observed abnormalities are transient or 
permanent. We did not evaluate neurohormonal activation, echocardiographic assess-
ment of tricuspid regurgitation, or measured hepatic blood flow, all of which could po-
tentially influenced the results. In our analysis, we have tried to exclude patients who 
were on hepatotoxic medication, but we cannot account for over-the-counter products 
with possible harmful effects on liver function, such as acetaminophen. Finally, we could 
not assess other reasons for liver test abnormalities in heart failures, such as hemochro-
matosis, because ferritin measurements were not routinely performed, and were there-
fore not available for this analysis.
Conclusion
Liver function abnormalities are frequently observed in patients with heart failure. Ele-
vated CVP showed the stron- gest relationship with liver function abnormalities. Despite 
interactions between CI and CVP, only AST, ALT, and total bilirubin were related to both 
CVP and CI, whereas both GGT and direct bilirubin were the most prominent parame- 
ters related to CVP, in the absence of reduced CI. Finally, the prognostic information of 
liver function abnormalities in heart failure was blunted by elevated CVP and low CI, 
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Abstract
Background
Elevated plasma concentrations of liver function tests are prevalent in patients with 
chronic heart failure (HF). Little is known about liver function in patients with acute HF. 
We aimed to assess the prevalence and prognostic value of serial measurements of liver 
function tests in patients admitted with acute decompensated HF. 
Methods
We investigated liver function tests from all 234 patients from the Pre-RELAX-AHF 
study at baseline and during hospitalization. The endpoints were worsening HF through 
day 5, 60 day mortality or rehospitalization and 180 day mortality.
Results
Mean age was 70±10 years, 56% were male and most patients were in NYHA III/IV 
(73%). Abnormal liver function tests were frequently found for ALT (12%), AST (21%), 
alkaline phosphatase (12%) and total bilirubin (19%), while serum albumin (0%) and 
total protein (1%) were not elevated. In-hospital changes were very small. On a continu-
ous scale, baseline ALT and AST were associated with 180 day mortality (HR (per dou-
bling)=1.52, P=0.030 and HR (per doubling)=1.97, P=0.013) and worsening HF through 
day 5 (HR (per doubling)=1.72, P=0.005 and HR (per doubling)=1.95, P=0.008). Albu-
min was associated with 180 day mortality (HR=0.86, P=0.001) but not with worsening 
HF (HR=0.95, P=0.248). Total protein was only associated with worsening HF (HR=0.91, 
P=0.004). 
Conclusions
Abnormal liver function tests are often present in patients with acute HF and are associ-
ated with an increased risk for mortality, rehospitalization and in-hospital worsening HF.
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Introduction
Abnormal liver function tests are frequently found in patients with heart failure.1 In 
chronic heart failure, the prevalence of abnormal liver function tests is 30-60%, depend-
ing on which liver function is measured.2,3 
Liver function tests are expected to be impaired due to hemodynamic changes.2 Im-
paired cardiac output mainly relates to aspartateaminotransferase (AST), alanineami-
notransferase (ALT) and bilirubin, while increased central venous pressure is related to 
all liver function tests, especially gamma-glutamyltranspeptidase (GGT), alkaline phos-
phatase (ALKP) and bilirubin.2,4,5 Pathophysiologic mechanisms other than hemody-
namic mechanisms, remain largely unknown. 
Liver function is less well studied in patients with acute heart failure.6-8 These patients 
are most likely to have impaired hemodynamics, making this group vulnerable to im-
paired liver function. Here, we study the prognostic value of (changes in) impaired liver 
function tests in patients with acute heart failure.
Methods
The Pre-RELAX-AHF (Relaxin for the treatment of patients with acute heart failure) 
was a multicentre, randomized, placebo-controlled, parallel-group, dose-finding phase 
IIb study, in which 234 patients with acute heart failure were recruited from 54 sites in 
8 countries and enrolled within 16 hours of presentation.9 Inclusion criteria were dysp-
noea, congestion on chest radiograph, increased brain natriuretic peptide (BNP) or N-
terminal pro-BNP (NT-proBNP), mild or moderate renal insufficiency and systolic blood 
pressure greater than 125 mmHg. Patients were randomly assigned to standard care plus 
48-hour intravenous infusion of placebo or relaxin in different doses. The study was ap-
proved by the relevant ethics board at every participating site, and all patients provided 
written informed consent.
Liver function tests
Liver function tests included aspartate aminotransferase (AST), alanine aminotrans-
ferase (ALT), alkaline phosphatase (ALKP), total bilirubin (Bili tot), albumin and total 
protein. Abnormal liver function tests were defined as values above the upper limit of 
normal. All of these liver function tests were measured at baseline, during hospitalization 
(day 1 to discharge/day 7) and day 14.
Endpoints
The endpoints of interest for this analysis were the composite endpoint of death and 
rehospitalization for heart failure within 60 days and death within 180 days. In-hospital 
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Table 1. Baseline characteristics.
All patients 
(N=234)
Age (years) 70.2 (10.5)
Male Sex 131 (56.0%)
Weight (kg) 81.2 (17.3)
Heart Rate (beats/min) 83.0 (15.9)
SBP (mmHg) 147.5 (19.9)
Ejection Fraction (%) 38.5 (14.3)






  Medical history
Hospitalized for HF (Past Year) 79 (34.2%)
Ischaemic Heart Disease 162 (70.4%)
Hypertension 198 (85.7%)
Diabetes 100 (43.9%)
Mitral Regurgitation 67 (29.0%)
Atrial Fibrillation/Flutter 109 (47.4%)
Laboratory values
Troponin (≥0.1 and <3x ULN) 38 (17.0%)
eGFR (MDRD formula) 53.6 (16.9)
Creatinine (umol/L) 115.0 (41.7)
BUN (mmol/L) 9.7 (4.1)
Sodium (mmol/L) 140.4 (3.9)
Hemoglobin (g/dL) 13.0 (1.8)
       Elevated (NT-pro-)BNP 140 (59.8%)
Treatment at baseline (%)
ACE Inhibitors 141 (62.1%)
ARB 12 (5.3%)
Beta blocker 131 (57.7%)
Aldosterone inhibitor 75 (33.0%)
Nitrates 50 (22.0%)





ALT (U/L) 21 (15-36)
    Above ULN 24 (12%)
AST (U/L) 26 (20-34)
    Above ULN 45 (21%)
Alkaline phosphatase (U/L) 84 (68-107)
    Above ULN 27 (12%)
Bilirubin (U/L) 10 (7-17)
    Above ULN 40 (19%)
Albumin (g/L) 40 (37-43)
    Above ULN 1 (0%)
Total Protein (g/L) 69 (64-72)
    Above ULN 3 (1%)
+ P-values computed for comparison of baseline 
congestion classification with two sided t-test for 
continuous variables and Chi-square test for categorical 
variables unless otherwise stated. * Wilcoxon Rank Sum
Values are presented as mean ± standard deviation, 
n (%) or median (25th-75th percentile). Elevated 
(NT-pro-)BNP is defined as NT-pro-BNP >= 3000 
or  BNP >= 250. Abbreviations: kg: kilogram; Adm.: 
administration; NYHA: New York Heart Association; 
AHF: Acute heart failure; ULN: upper limit of normal; 
eGFR: estimated Glomerular filtration rate; SBP: systolic 
blood pressure; BUN: blood urea nitrogen; NT-proBNP: 
N-terminal pro-BNP; BNP: brain-type natriuretic 
peptide; ACE: angiotension converting enzyme; 
ARB: angiotensin receptor blocker; ALT: alanine 
aminotransferase; AST: aspartate aminotransferase.
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worsening heart failure was defined by a physician-assessment through day 5 on the basis 
of worsening signs or symptoms of heart failure together with the need for addition or 
initiation of intravenous medications or mechanical support to treat acute heart failure.
 
Statistical analyses
Data are presented as mean ± standard deviation when normally distributed, as median 
and interquartile range when non-normally distributed, and as frequencies and percent-
ages for categorical variables. Differences between groups were evaluated by Student’s t 
test, Wilcoxon rank sum, or Chi-square tests, when appropriate. Linear regression analy-
ses were used to identify associations with liver function tests.
Cox proportional hazards models were used to estimate hazard ratios and 95% con-
fidence intervals for a 1-unit change for baseline predictors of all-cause mortality and 
the combined endpoint of all-cause mortality or HF rehospitalization. Restricted cubic 
splines were used to examine the linearity assumption of the predictors with outcome and 
appropriate transformations were applied to predictors that were nonlinear. For non-lin-
ear predictors a log2 transformation was used and the associated HR can be interpreted 
as the hazard associated with a doubling of the value. Univariable summaries, adjusted 
for baseline value, were also provided to examine the association between improvement 
at day 5 and at any time to day 5 in liver function tests with outcome. Kaplan-Meier 
curves and a log-rank test were performed to assess the effect of baseline liver function 
tests by quartile on outcome.
A P value < 0.05 was considered statistically significant. Data were verified and analyzed 
using commercially available software (SAS, version 9.2; SAS Institute, Inc).
Figure 1. Change of liver function tests during hospitalization.















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Baseline characteristics are presented in table 1. Mean age was 70 ± 10 years and 56% 
were male. Systolic blood pressure at baseline was 148 ± 20 mmHg, and most were most 
patients were in NYHA III (45%) and IV (29%). Seventy percent had a history of ischemic 
heart disease. 
Prevalence of liver function tests
Liver function tests were abnormal for ALT (12%, median 21 U/L, [25th percentile 15 
U/L - 75th percentile 36 U/L], AST (21% median 26 U/L [20 U/L - 34 U/L]), ALKP (12%, 
median 84 U/L [68 U/L - 107 U/L]) and total bilirubin (19% median 10 umol/L [7 umol/L 
- 17 umol/L]), while albumin (0%, median 40 g/L [37 g/L - 43 g/L]) and total protein (1%, 
median 69 g/L [64 g/L - 72 g/L]) were mostly normal. Figure 1 shows that there were no 
substantial changes in liver function tests during hospitalization up to day 14. 
Prognosis
On a continuous scale, higher ALT (HR 1.52 (1.04-2.21) per doubling, P = 0.030), high-
er AST (1.97 (1.15-3.37) per doubling, P = 0.013) and lower albumin (HR 0.86 (0.78-
0.94), P = 0.001) were associated with 180 day mortality. For the combined endpoint 
of mortality or rehospitalization through day 60, higher ALT (HR 1.45 (1.01-2.07) per 
doubling, P = 0.043), higher AST (HR 1.89 (1.14-3.13) per doubling, P = 0.013), lower 
albumin (HR 0.86 (0.79-0.93), P < 0.001) and higher ALKP (HR 1.01 (1.00-1.02), P = 
0.026) had a significant association, while lower total protein showed a trend (HR 0.94 
(0.88-1.00), P = 0.068). 
Worsening heart failure was associated with higher baseline value of ALT (HR 1.72 
(1.18-2.49) per doubling, P = 0.005), higher AST (HR 1.95 (1.19-3.20) per doubling, P = 
0.008), and lower total protein (HR 0.91 (0.85-0.97), P = 0.004).
These results are confirmed when liver function tests are divided into quartiles. In figure 
2, higher quartiles of ALT (P = 0.005) and AST (P = 0.036) and lower quartiles of albumin 
(P = 0.046) are related with higher rates of mortality through day 180. For the combined 
endpoint of mortality or rehospitalization through day 60, higher quartiles of ALT (P = 
0.019) and ALKP (P = 0.030), and lower quartiles of albumin (P = 0.015) and total protein 
(P = 0.026) are associated with worse prognosis (Figure 3).
Only change in albumin was significantly associated with all-cause mortality (HR 0.09 
per unit increase (0.02-0.45), P = 0.004). No other significant changes between change in 
liver function test and prognosis could be found, but it should be noted that 95% confi-
dence intervals were wide (Table 3). 
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Figure 2. Mortality per quartiles of each liver function test (through day 180).
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Figure 3. Death or HF-hospitalization per quartiles of each liver function test (through day 60).
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Discussion
Abnormal liver function tests were often present in patients with acute heart failure 
with ALT, AST and albumin being associated with an increased mortality, rehospitaliza-
tion risk and in-hospital worsening heart failure. We did not find an association between 
changes in liver function tests and prognosis.
Prevalence
Abnormal liver function tests are frequently found in patients with chronic heart fail-
ure with a prevalence between 30-60%, depending on which liver function test is meas-
ured.1-3,10,11 However, liver function is less well studied in patients with acute heart fail-
ure.6-8
We found that abnormal liver function tests are prevalent in patients with acute heart 
failure as well. We found that 20% of patients with acute heart failure had abnormal AST 
and total bilirubin, 10% had abnormal ALT and ALKP but almost no patients had abnor-
mal levels of albumin and total protein. These results are similar with previous reports, 
with the exception of albumin which had a prevalence of 17-44% in other studies.6,7 We 
also found that liver function tests changed minimally during hospitalization, which was 
similar to a previously published report.6
Pathophysiology 
Abnormal liver function tests show a relationship with elevated central venous pressure 
and reduced hepatic perfusion.2,4,5,8,12 The pathophysiology of liver failure in heart failure 
patients consists of hepatic hypoxic injury, due to reduced cardiac output, and necrosis in 
the central zone of hepatic lobules originating from direct compression and congestion.11 
In other words, low hepatic perfusion in heart failure mainly predisposes to hepatocel-
lular liver injury (high AST and ALT), whereas cholestatic liver injury (high bilirubins, 
GGT, ALKP) is primarily observed when congestion is present.2 
In a previous study in patients with chronic heart failure, we found that none of the liver 
function tests remained associated with mortality after adjustment for hemodynamic fac-
tors (congestion and cardiac output).2 This suggests that the abnormal liver function tests 
are a reflection of the poor hemodynamic status, instead of secondary hepatic injury. 
Nevertheless, liver function tests could be useful as an easy prognostic assessment in the 
acute setting.
Interestingly, when cardiac function is restored by a left ventricular assist device, AST, 
ALT and total bilirubin return to normal within 1 or 2 months, further suggesting that 
impaired haemodynamics in patients with heart failure are the cause of abnormal liver 
function tests.13 Non-hemodynamic factors, such as poor nutrition, can lead to fatty liver 
and fibrosis, and are therefore associated with decreased liver function in heart failure 
patients.14 Vice versa, decreased liver function can lead to worsening heart failure due to 
hypoalbuminemia and low-osmolalic state, causing fluid overload and oedema.5
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Prognosis
In chronic heart failure, some reports show that especially bilirubin is associated with 
mortality, while other individual reports show, mostly univariate, an inconsistent prog-
nostic value of AST, ALKP and gamma-glutamyl transpeptidase (GGT).3,15,16 
In three different studies in patients with acute heart failure, AST, ALT and ALKP were 
associated with 180 day mortality in 1134 patients;8 AST, ALT and albumin were associ-
ated with 180 day mortality in 189 patients;7 and albumin and bilirubin were associated 
with 180 day mortality in 2061 patients.6 Two other studies showed prognostic value of 
total bilirubin levels.3,16 In the present study we found that especially AST and ALT were 
associated with worse prognosis. Furthermore, decreased albumin was associated with 
mortality and decreased total protein was associated with in-hospital worsening heart 
failure. 
Combining these results, we observed that mainly hepatocellular damage (AST and 
ALT) is related to mortality in patients with acute heart failure. Nevertheless, other stud-
ies have also reported that cholestatic profiles (bilirubin and ALKP) of liver function 
abnormalities can be related with prognosis.3,15,16
Except for a change in albumin, we did not find other statistically significant associa-
tions between changes in liver function overtime and clinical outcome, in contrast to 
other studies.6,18 This might be related to the small sample size of our study. While the 
present study may yield meaningful results with respect of the prognostic significance of 
baseline values of the liver exams, it may be too small to allow an assessment of the prog-
nostic value of changes in these exams, where interindividual variability is likely larger. 
In a much larger study, changes in liver exams during hospitalization were clearly related 
with mortality.18 
Limitations 
Although most liver function tests were available for the analysis, we did not have values 
for gamma-glutamyltransferase (GGT). We did not have information about neurohor-
monal activation, echocardiographic assessment of tricuspid regurgitation, hepatic blood 
flow, or hepatotoxic medication which could influence the results. 
An important limitation of this study is its limited sample size, and therefore its limited 
statistical power, as indicated before. 
Conclusion
We found that abnormal liver function tests are often present in patients with acute 
heart failure and are associated with increased mortality, rehospitalization and in-hospi-
tal worsening heart failure.
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Abstract 
Heart failure is a clinical syndrome characterized by poor quality of life and high mor-
bidity and mortality. Comorbidities frequently accompany heart failure and further de-
crease in both quality of life and clinical outcome. We describe that the prevalence of 
comorbidities in patients with heart failure is much higher compared to age-matched 
controls. We will specifically address the most studied organ-related comorbidities, that is, 
renal dysfunction, cerebral dysfunction, anaemia, liver dysfunction, chronic obstructive 
pulmonary disease, diabetes mellitus and sleep apnoea. The pathophysiologic processes 
underlying the interaction between heart failure and comorbid conditions are complex 
and remain largely unresolved. Although common risk factors are likely to contribute, it 
is reasonable to believe that factors associated with heart failure might cause other co-
morbid conditions. Inflammation, neurohumoral pathway activation and hemodynamic 
changes are potential factors. We try to provide explanations for the observed association 
between comorbidities and heart failure, as well as its impact on survival.
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Introduction
Heart failure is a clinical syndrome characterized by poor quality of life and high mor-
bidity and mortality. Moreover, patients with heart failure often suffer from multiple co-
morbidities that further impair quality of life and prognosis.1 Braunstein et al. found that 
40 % of patients with heart failure had 5 or more non-cardiac comorbidities.2
Heart failure itself carries a poor prognosis, with a 5-year survival rate of only 50 % de-
spite optimal therapy.1 The presence of comorbidities impairs survival further still (Table 
1). There is a strong association between non-cardiac comorbidities and adverse clinical 
outcomes. Hospitalization rates increase when comorbidities are present. Patients with 
multiple comorbidities account for 81 % of all hospital days experienced by all heart fail-
ure patients.2
The pathophysiologic processes underlying the interaction between heart failure and 
comorbid conditions are complex and remain largely unresolved. Inflammation, neuro-
humoral pathway activation and shared risk factors each have an effect, as do hemody-
namics. Heart failure causes hypoxia and insufficient perfusion of organs.3,4 Other reports 
also show that organ dysfunction can be caused by increased venous pressure.5,6
In this review, we describe comorbidities that have been documented in patients with 
heart failure (Table 1) and subsequently specifically address the most studied organ-relat-
ed comorbidities, that is, renal dysfunction, cerebral dysfunction, anaemia, liver dysfunc-
tion, chronic obstructive pulmonary disease (COPD), diabetes mellitus and sleep apnoea. 
We try to provide explanations for the observed association between the comorbidities 
and heart failure, as well as their impact on survival. 
Prevalence of comorbidities in heart failure compared with age-
matched controls 
Prevalence of comorbidities is high in patients with heart failure.2 This can partly be 
explained by the higher age of patients with heart failure, as elderly patients are more 
likely to have comorbid conditions. However, there is evidence to suggest comorbidities 
in patients with heart failure are more prevalent than in age-matched controls. In order 
to assess the prevalence of comorbidities in patients with heart failure compared to age-
matched controls, we used data from Dutch institutions, including reports and National 
Public Health Compass data from the Institute for Public Health and the Environment 
(RIVM) and GP registries.
These data indicate that renal dysfunction (35 vs. 5 %), sleep apnoea (60 vs. 1 %), anae-
mia (50 vs. 15 %), diabetes mellitus (20 vs. 13 %), liver dysfunction (40 vs. 10 %) and 
chronic obstructive pulmonary disease (40 vs. 30 %) are present much more frequently in 
patients with heart failure (Figure 1). On a critical note, definitions for the presence of co-
morbidities may vary, and reported prevalence figures for comorbidities in patients with 
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heart failure may be overestimated due to selection bias. Nevertheless, comorbidities in 
patients with heart failure seem to be higher compared to healthy patients of similar age.
Specific comorbidities related with heart failure
Anaemia 
Prevalence
About 37 % of heart failure patients have anaemia, but prevalence varies widely due to 
different definitions and disease severity.7 The World Health Organisation criteria are 
most commonly used, defining anaemia as haemoglobin <12 g/dL (7.5 mmol/L) in wom-
en haemoglobin <13 g/dL (8.1 mmol/L) in men. 
Pathophysiology 
Renal failure is an important factor in the complex relationship between anaemia and 
heart failure (e.g. intrinsic renal disease, renal artery stenosis). Other factors include 
lower levels of erythropoietin, raised central venous pressure and low arterial pressure.4,8 
Because renal dysfunction is related to both anaemia and heart failure, a vicious circle 
may be present, named the cardiorenal anaemia syndrome.9
Figure 1. Prevalence of comorbidities in heart failure: Prevalence of comorbidities in patients with heart failure 
(dark) compared to age-matched controls.
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There are several pathways via which heart failure can cause anaemia. Firstly, neuro-
hormonal activation (renin–angiotensin–aldosterone system (RAAS) and vasopressin is 
accompanied by salt and fluid retention, leading to increased extracellular volume and 
lower haemoglobin levels (‘pseudoanaemia’).10 Although this so-called pseudoanaemia is 
related to fluid retention, it is not accompanied by signs and symptoms.10
Secondly, heart failure is accompanied by haematinic deficiencies. The mechanism is 
probably related to poor intake, blood loss due to aspirin or warfarin, malabsorption and 
cardiac cachexia.11 Of patients with anaemia and heart failure, half are iron deficient and 
less than one-third are B12- or folate deficient.12,13
Thirdly, heart failure is associated with a low-systemic state of inflammation.5 Chronic 
inflammation leads to anaemia due to erythropoietin (EPO) resistance as well as reduced 
bone marrow proliferation.14
Fourthly, patients without anaemia also showed deficient bone marrow function.15 
Intrinsic pathways for these effects are seen in vitro, suggesting general dysfunction of 
haematopoietic cells is present in patients with heart failure even without serum effects.
Finally, the use of heart failure medication (i.e. ACE inhibitors and beta-blockers) might 
also be associated with the prevalence of anaemia. Intervention in RAAS activation leads 
to lower haematopoietic activity.16 In the SOLVD trial, the risk of anaemia increased by 
more than 50 % in patients randomized to enalapril.17 This may be explained by N-acetyl-
seryl-aspartyl-lysyl-proline (Ac-SDKP), as levels of this erythropoiesis-inhibiting factor 
Table 1. All comorbidities in heart failure: Summary of all comorbidities in heart failure, including prevalence, 
hazard ratio for mortality and number of articles by MeSH-search.




Anaemia 37 Yes 1.010
Cerebral dysfunction 28-58 Yes 407
Cognitive dysfunction 50-60 Yes 116
COPD 10-50 Yes 449
Depression 22 Yes 577
Diabetes 6-44 Yes 2.100
Erectile dysfunction 85 - 36
Gout/hyperuricemia - Yes 34
Hypertension 60-70 Yes 4.734
Iron deficiency 50-60 Yes 168
Kidney dysfunction Up to 55 Yes 1.610
Liver dysfunction 30-60 Yes 521
Sleep apnoea 60 Yes 641
Stroke 5 Yes 720
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increased due to ACE inhibitors, resulting in decreased haematopoiesis and anaemia.16 
Use of beta-blockers has also been related to a higher occurrence of anaemia.18
Impact on survival
Anaemia is associated with increased mortality and morbidity in patients with heart 
failure. In a meta-analysis of 150,000 patients with chronic heart failure, 47 % of anaemic 
patients died with a minimal follow-up of 6 months compared with 30 % in the non-
anaemic group.7 In a registry of more than 1 million patients, anaemia had an additive 
prognostic effect to heart failure and renal failure; annual mortality was 4 % in patients 
without heart failure, renal failure and anaemia and rose to 23 % in patients with the com-
bination of all three.19 Interestingly, patients with pseudoanaemia had a worse prognosis 
than those with true anaemia.20
In short, about one-third of patients with heart failure have anaemia, depending on 
the definition used and disease severity. The underlying pathophysiology is complex and 




Cognitive impairment has a prevalence of 28–58 % in patients with heart failure.21–23 In 
a systematic review, the risk for the presence of cognitive impairment increased by more 
than 60 % in patients with heart failure compared to control subjects.21 However, incon-
sistent definitions of cognitive impairment are used as cognition is a complex system with 
several domains.24,25 Therefore, multiple different assessments are advised.
Pathophysiology
The aetiology of cognitive impairment in patients with heart failure is largely unclear, as 
only a limited number of heart failure studies have systematically assessed the cognitive 
function. Nevertheless, it is thought that loss of cerebral function in patients with heart 
failure is partly due to a higher rate of cerebral infarcts and cerebral atrophy and may be 
explained by atherosclerosis as a common risk factor. However, cerebral hypoperfusion 
is another possible cause for cerebral abnormalities, and significant regional blood flow 
abnormalities were found in patients with heart failure.26 However, it should be noted that 
the brain is relatively protected by strongly developed autoregulatory mechanisms. Hy-
pothetically, with further deterioration in cerebral blood flow, autoregulation will even-




Little is known about mortality rates relating to cerebral dysfunction. In a small num-
ber of studies, both cognitive impairment and dementia were associated with increased 
mortality.27,28 Speculatively, cognitive impairment may contribute to hospitalization and 
worsening heart failure because it leads to the inability to manage complex medical re-
gimes and failure to recognize worsening clinical status.29
In brief, cognitive impairment in heart failure is higher than in controls, with a preva-
lence of up to 58 %. Although vascular disease could be a common pathway, the brain is 
potentially another organ influenced by hemodynamic profiles.
Chronic obstructive pulmonary disease
Prevalence
Chronic obstructive pulmonary disease and heart failure often occur in the same pa-
tient. The diagnosis of either is difficult, as both diseases result in symptoms of restrictive 
and obstructive pulmonary abnormalities in combination with muscular changes.30 The 
prevalence of chronic obstructive pulmonary disease in patients with heart failure ranges 
from 10 to 50 %, where recent studies tend to report higher percentages.31 Compared with 
general population, the prevalence of chronic obstructive pulmonary disease in patients 
with heart failure was seven times higher in a large Scottish database.32
Notably, prevalence was often based on self-reporting, whereas spirometry would be 
preferable. In fact, only 43 % of patients with evidence of COPD during spirometry self- 
reported the presence of COPD, highlighting the need for better screening for this co-
morbidity.33
Pathophysiology
The common prevalence may be caused by common risk factors. Smoking is an ob-
vious common risk factor. Other possible mechanisms include inflammation, hypoxia, 
oxidative stress and sympathetic nervous system malfunction.34 For instance, low-grade 
inflammation is observed in heart failure and plays a role in the atherosclerotic process, 
and there is abundant evidence of systemic inflammation in patients with COPD.35 Other 
suggested mechanisms include development of interstitial fibrosis, reduced lung volume 
due to cardiomegaly and interstitial and alveolar fluid, and weakness of the respiratory 
muscles.36
COPD may also cause heart failure by increasing pulmonary blood pressure. A small 
study showed that patients with COPD display both left and right ventricular dysfunc-
tion.37 This may partly explain the high cardiovascular mortality among patients with 
COPD.
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Impact on survival
COPD limits survival substantially. Survival is strongly correlated with pulmonary 
function as well as self-reported COPD.33
In summary, the prevalence of COPD in heart failure ranges up to 50 %. This is seven 
times higher than in age- matched controls. While the pathophysiologic link is unclear, 
smoking and inflammation as common risk factors may be part of the explanation.
Diabetes
Prevalence
Prevalence of both diabetes and heart failure is increasing dramatically worldwide.38 
The prevalence of diabetes is 4–7 % in the normal population and ranges from 12 to 44 
% in patients with heart failure, depending on the severity of heart failure and whether a 
decreased left ventricular ejection fraction is present.
Pathophysiology
The incidence of diabetes in heart failure is higher than in patients without heart failure 
(odds ratio 1.6) with an absolute incidence of diabetes in patients with heart failure of 28 
% over 3 years.39 In diabetic patients, heart failure is twice as common in men and five 
times as common in women, compared with age-matched controls.40
Heart failure is associated with impaired glucose metabolism and poor glycaemic con-
trol. In addition, the severity and progression of heart failure is associated with increased 
insulin resistance.41 The risk of development of heart failure is also increased in patients 
with diabetes and impaired glucose tolerance.42
Diabetes is believed to cause metabolic derangement in the heart in addition to con-
tractile dysfunction and loss of normal microvasculature.43 This results in a higher rate of 
myocardial infarction in diabetic patients and affects left ventricular ejection fraction.44 
These underlying mechanisms are encompassed by the controversial entity ‘diabetic car-
diomyopathy’.43 Changes in the diabetic heart include intramyocardial microangiopathy, 
the accumulation of collagen and other glycation end-products and increased turnover 
of free fatty acids.44
Another explanation is that mutual entities may predispose to both diabetes and heart 
failure. The Framingham and SOLVD studies found that diabetic patients were more 
obese, had impaired lipid and glucose profiles and had more hypertension.45,46 Patients 
with diabetes are also more at risk for developing coronary artery disease, predisposing 
them to the development of heart failure.
Impact on survival
Cardiovascular morbidity and mortality is increased in patients with diabetes.47 Accord-
118 Chapter 7
ingly, patients hospitalized with heart failure and diabetes have worse outcome than pa-
tients with only heart failure.48
In short, heart failure and diabetes frequently coexist. Pathophysiologic mechanisms 
remain unclear although common pathways may exist. Prognosis is worse when diabetes 
mellitus is present in patients with heart failure.
Kidney dysfunction
Prevalence
Chronic kidney disease is usually defined as an estimated glomerular filtration rate 
(eGFR) below 60 mL/min/1.73 m2. Chronic kidney disease is probably the best known 
comorbidity in patients with heart failure, with a prevalence ranging up to 55 %.4,49
Pathophysiology
The common coexistence of cardiac and renal failure could be explained by a major 
common risk factor for both heart failure and renal disease, such as (coronary) arterial 
disease, hypertension or diabetes. On the other hand, there seems to be a reciprocal rela-
tionship, in which cardiac failure can cause renal failure and vice versa. For example, con-
gestion in heart failure has been shown to be a predictor of renal function, while patients 
with end-stage renal disease often develop cardiac dysfunction.4,50 The pathophysiology 
of concomitant renal dysfunction in heart failure is strongly related to both decreased 
cardiac output and increased central venous pressure.51,52 Increased central venous pres-
sure can compromise renal perfusion as well. Furthermore, several neurohormonal path-
ways (e.g. RAAS) and heart failure therapies have a negative impact on renal function and 
vasoactive agents and can thereby modulate the relationship between haemodynamics 
and renal function.53
Chronic kidney dysfunction (CRS type 4) is known to be associated with worse cardio-
vascular outcome.54 Next to shared risk factors like smoking, obesity, hypertension and 
dyslipidaemia, other pathological factors may be involved. Observations from specific 
biomarker studies suggest a pathophysiologic mechanism involving chronic inflamma-
tion, subclinical infections and accelerated atherosclerosis, which predisposes to the de-
velopment of heart failure.
Impact on survival
Renal function is a well-known predictor of morbidity and mortality in patients with 
heart failure.55 In a registry of more than 1 million patients, the risk of mortality increased 
in patients who had both heart failure and renal dysfunction, compared to patients with 
heart failure or renal dysfunction alone.19 Deterioration of renal function over time is also 
a potent predictor of mortality and hospitalization, resulting in a 60 % increase in relative 
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risk compared to patients with stable renal function.56
In summary, chronic kidney disease is a well-known comorbidity in patients with heart 
failure with a prevalence ranging up to 55 % and is related to poor prognosis. Among 
other factors, such as hypoperfusion, medication, neurohormonal and inflammatory ac-
tivation, decreased cardiac output and increased central venous pressure might explain 
its common prevalence and subsequent poor prognosis.51,57
Liver dysfunction
Prevalence
The presence of liver enzyme abnormalities in heart failure has long been recognized.58 
We and others have shown that abnormal liver enzymes are frequently found in patients 
with heart failure, with a prevalence of 30–60 %, depending on which liver enzyme is 
measured.6,59
Pathophysiology
Interestingly, most abnormal liver enzymes show a relationship with increased venous 
congestion, while only some seem to be related to reduced cardiac output. Decreased 
cardiac output mainly relates to aspartateaminotransferase (AST), alanineaminotrans-
ferase (ALT) and bilirubin, where increased central venous pressure is related to all liver 
enzyme tests, especially gamma-glutamyltranspeptidase (GGT), alkaline phosphatase 
(ALP) and bilirubin.6,60
When heart function is restored by a left ventricular assist device, liver enzyme levels, 
specifically AST, ALT and total bilirubin, return to normal within 1 or 2 months, pro-
viding further evidence that impaired haemodynamics in patients with heart failure are 
the cause of abnormal liver enzyme levels.61 This is in agreement with individual small 
reports that highlight the importance of either high central venous pressure or reduced 
hepatic perfusion.60,62 One reason why low perfusion could be less important for liver 
function may be the fact that oxygen consumption can easily be increased even if hepatic 
blood flow is decreased. The liver is dependent on the blood supply delivered by the he-
patic artery, but this accounts for only 30 % of the blood received. The remaining 70 % 
comes from the portal system.63 In contrast, the liver is directly connected to the central 
venous system, which could explain its sensitivity to raised central venous pressure. Vice 
versa, liver dysfunction can lead to increased fluid overload due to hypoalbuminemia and 
low-osmolality state, potentially leading to worsening of heart failure.
Impact on survival
With regard to prognosis, several reports have addressed the prognostic importance 
of liver enzyme abnormalities in the setting of heart failure.59,64 However, it is possible 
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that the relation between abnormal liver enzymes and impaired prognosis is due to the 
relationship between liver enzymes and congestion. We found that levels of GGT, ALP, 
AST and LDH were predictors of all-cause mortality. Even after adjustment for easily ob-
tainable non-invasive covariates, AST and LDH remained significant predictors of prog-
nosis, but not independently of CVP and cardiac index.6 This suggests that liver enzyme 
abnormalities are a reflection of poor hemodynamic status in these patients, rather than 
an underlying secondary hepatic injury that leads to worse prognosis.
In summary, abnormal liver enzymes have prevalence up to 60 %, which is higher than 
in age-matched controls. Elevated liver enzymes seem to be related to a combination of 
congestion and reduced cardiac output. Low hepatic perfusion in heart failure mainly 
predisposes to hepatocellular liver injury (high AST, ALT and bilirubins), whereas chole-
static liver injury (high bilirubins, GGT and ALP) is primarily observed when conges-
tion is present. Bilirubin levels are dependent of both reduced perfusion and congestion. 
Although individual abnormal liver enzyme levels are related to higher mortality, this 
merely seems to reflect poor hemodynamic status.
Sleep apnoea
Prevalence
The sleep apnoea syndrome is characterized by complaints of daytime sleepiness and 
repetitive breathing cessation during sleep. This syndrome can be divided into two main 
subcategories: obstructive sleep apnoea syndrome (OSAS) and central sleep apnoea syn-
drome (CSAS). Sleep apnoea syndrome (SAS) is a condition often unrecognized in heart 
failure patients, as excessive sleepiness has a symptomatic overlap with heart failure. Both 
OSAS and CSAS can be present in heart failure, with CSAS being far more common.65 
The prevalence of SAS in heart failure is about 60 %, while it affects 2–4 % of the middle-
aged working population.66
Pathophysiology
CSAS with a crescendo and decrescendo flow pattern (so-called Cheyne Stokes) may be 
considered a consequence of heart failure and is largely driven by changes in pCO2. Pa-
tients with chronic heart failure have high filling pressures which can lead to pulmonary 
oedema, especially at night. As a consequence, pulmonary J receptors are stretched, lead-
ing to hyperventilation. PaCO2 subsequently drops under the so-called apnoea thresh-
old and the patient stops breathing.67 The apnoea and/or hypopnea that arises causes an 
imbalance in the myocardial oxygen delivery/consumption ratio, as well as activation of 
sympathetic and other neurohumoral systems and increasing right and left ventricular 
afterload.68 In turn, the filling pressure will increase, feeding into a vicious circle.
 OSAS is caused by a combination of abnormalities in pharyngeal anatomy, pharyngeal 
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function and ventilatory control during sleep. OSAS is a risk factor for cardiovascular 
diseases and hypertension and can lead to heart failure.69
Impact on survival
Both OSAS and CSAS are associated with increased mortality.70,71 After adjustment for 
confounders, patients with both heart failure and SAS have a mortality rate twice that of 
patients with heart failure alone.
In brief, sleep apnoea is more prevalent in heart failure than age-matched controls, often 
goes unrecognized and is related with mortality. Central sleep apnoea is the most com-
mon variant in patient with heart failure, with hemodynamic factors playing a patho-
physiologic role.
Other comorbidities
Previously discussed comorbidities are the most studied organ-related comorbidities. 
Many other comorbidities are prevalent in patients with heart failure (Table 1). These co-
morbidities will become an increasingly common problem as patients with heart failure 
are getting older.
Heart failure is accompanied by a two- to threefold increased risk of stroke compared 
to controls. There is an annual stroke rate of 1.3–3.5 %, but up to 16 % in patients with 
concomitant atrial fibrillation.72 The prevalence of stroke is about 5 % in patients with 
heart failure. Because of newer high-resolution magnetic resonance imaging techniques, 
the prevalence of silent strokes is found to be between 20 and 40 %.73,74 There are several 
mechanisms associated with increased stroke risk in patients with heart failure.73 The 
most recognized reason for stroke in heart failure patients is cardioembolic stroke due to 
atrial fibrillation and/or left ventricular hypokinesia.75,76 Secondly, there is a hypercoagu-
lable state due to the activation of the sympathetic nervous system, activation of the re-
nin–angiotensin–aldosterone system and presence of endothelial dysfunction.77,78 Stroke 
in heart failure patients is associated with a poorer outcome and higher mortality.79
Patients with heart failure often have cognitive impairment, with a prevalence of up 
to 50–60 %.21,80 The underlying pathophysiological mechanisms are difficult to identify 
and are still unclear, but cerebral hypoperfusion and multiple cardiogenic emboli provide 
possible explanations.21 Also, cognitive dysfunction may coincide with heart failure. Evi-
dence suggests that low cardiac output is independently associated with impairment of 
multiple cognitive domains.81 In fact, multiple studies reported significant improvement 
in cognitive function in patients who had received transplants.82,83 Cognitive dysfunction 
is associated with a poor prognosis, but it remains unclear whether this is a direct effect 
of heart failure per se21, or whether it reflects general cardiovascular risk markers that are 
associated with cognitive dysfunction.84
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Erectile dysfunction has a prevalence of 85 % in patients with heart failure with an av-
erage age of 60 years.85 The pathophysiology can be divided into intrinsic and extrinsic 
factors. Intrinsic factors include decreased cardiac output, decreased exercise capacity 
and neurohormonal and vascular changes, including atherosclerosis. Extrinsic factors are 
psychological factors and side effects from medications.86
Pathophysiologic explanations for high prevalence of comorbid-
ities in heart failure
In the previous section, the prevalence of comorbidities was shown to be much higher 
in heart failure patients compared to an age-matched population. Higher prevalence fig-
ures suggest a common risk factor or a causal relationship.
A common risk factor as a common cause may be challenged, as it is unlikely that one 
factor can cause all comorbidities including heart failure. Moreover, because all comor-
bidities have heart failure as a common denominator, it is likely that heart failure may 
cause or worsen predisposed comorbidities. Therefore, a causal relationship, where heart 
failure and other comorbidities may aggravate each other, seems to be more likely. Several 
mechanisms in heart failure may contribute to failure of other organs. Firstly, heart failure 
causes neurohormonal changes that cause other organs to dysfunction. Heart failure can 
change neurohormonal status by affecting these balances—for instance, hormonal (an-
giotensin and vasopressin), neural (parasympathetic and sympathetic nerves), structural 
(hypertrophy and remodelling) and local factors (pH, ions and adenosine).87
Secondly, the drugs used to treat heart failure may affect comorbidities (e.g. beta-block-
ers and COPD; ACE inhibitors and kidney dysfunction and anaemia).
Thirdly, hemodynamic changes might cause other organs to fail as well. Hemodynamic 
derangements are the hallmark of the heart failure syndrome, and because the heart pro-
vides perfusion for the entire body, a deterioration of cardiac output affects all organs. 
Interestingly, blood is redistributed to certain organs at the expense of others.87 In mild 
heart failure, resting cardiac output is still normal, but during exercise, the increase in 
cardiac output is suppressed, leading to a smaller increase in skeletal muscle blood flow. 
In patients with severe heart failure, however, resting cardiac output is already reduced. 
The heart and brain receive normal blood flow at the expense of skeletal muscle and renal 
blood flow. As a percentage of cardiac output, cerebral and coronary blood flows are even 
increased.3 Patients with heart failure can be divided into four hemodynamic profiles, 
based on whether or not forward failure (low perfusion) and backward failure (conges-
tion) are present.88 Further research is needed to establish which patients with heart fail-
ure are susceptible to developing comorbidities. Although associations have been found 
between heart failure and various diseases and organ dysfunctions, evidence for a causal 
relation is largely lacking. Ultimate proof should come from intervention studies aimed 
at improving the function of one selected organ and that study the effects on the other 
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organ(s). So far, proposed pathophysiologic explanations are largely speculative, and fur-
ther research should be focussed on elucidating common pathophysiology and potential 
treatment targets.
Conclusion
The prevalence of comorbidities in heart failure patients is much higher compared to 
non-heart failure patients of similar age. Although common risk factors are likely to con-
tribute, it is reasonable to assume that heart failure itself may be the cause of comorbidi-
ties. Chronic underperfusion of organs as well as increased venous pressure secondary 
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Heart failure is a clinical syndrome characterized by the heart’s inability to meet the 
body’s circulatory demands. It can cause a number of symptoms, including dyspnea, 
edema and exercise intolerance.1 Patients with heart failure have a poor quality of life 
and high morbidity and mortality.2 In recent decades, growing evidence has accumulated 
about other diseases and dysfunction of other organs in patients with heart failure. These 
‘comorbidities’ frequently accompany heart failure and result in worse quality of life and 
clinical outcome.
Aims
This thesis aimed to assess:
1. The prevalence of individual and multiple comorbidities in patients with heart fail-
ure;
2. Whether the prevalence of comorbidities is higher in patients with heart failure 
than in age-matched controls 
3. The pathophysiologic mechanisms connecting heart failure and individual comor-
bidities as well as determinants of multiple comorbidities
4. The prognostic influence of individual and multiple comorbidities.
Comorbidities
While numerous studies focus on a single comorbidity, only few previous studies fo-
cused on multiple non-cardiac comorbidities in patients with heart failure.3,4 However, 
regional differences have not been studied and determinants of multiple co-morbidities 
remain unknown. 
Chapter 1 examines multiple comorbidities in a broad spectrum of European patients 
with chronic heart failure. A total of 3226 outpatients with chronic heart failure were 
included in this analysis. We focused on the prevalence, determinants, regional variation 
and prognostic implications of comorbidities.
We conclude that the majority of patients had a least one comorbidity, and the number 
of comorbidities increased with the severity of heart failure. The presence of diabetes, 
chronic kidney disease and anemia were independently associated with increased risks 
of mortality and heart failure hospitalizations, with the highest population attributable 
risks for chronic kidney disease and anemia. Interestingly, there were marked differences 
in prevalence and prognostic implications of comorbidities in various regions across Eu-
rope.
The pathophysiologic mechanisms connecting heart failure and comorbidities remain 
largely unknown. These mechanisms are complex and may be different for individual 
comorbidities. Therefore, comorbidities must be studied separately to find pathophysi-
ologic associations.
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Of all the comorbidities, only two are directly related to an organ – renal and liver dys-
function. Anemia, for example, is studied in blood and related to bone marrow dysfunc-
tion and renal dysfunction. Other comorbidities, such as sleep apnea and cognitive dys-
function, do not have clear substrates that could be easily studied.
Renal dysfunction and liver dysfunction are relatively easy to study and can be evalu-
ated on a continuous functional scale rather than dichotomized into dysfunctional or not.
Renal dysfunction
One of the most important comorbidities in heart failure is renal dysfunction. Renal 
dysfunction is a strong, independent predictor of prognosis in the general population 
and in patients with heart failure.5,6 Heart failure and renal dysfunction share risk factors 
- hypertension, diabetes, and underlying atherosclerotic disease. Moreover, heart failure 
can cause renal dysfunction and vice-versa. The complex reciprocal interaction is called 
the cardiorenal syndrome.7 Cardiorenal syndrome is classified into 5 subtypes, according 
to the underlying pathophysiologic mechanisms. We are interested in cardio-renal syn-
drome types 1 (acute) and 2 (chronic) - acute/chronic abnormalities in cardiac function 
that result in acute/chronic kidney disease.
In chapters 2-4 we assess the prevalence of renal dysfunction in patients with chronic 
and acute decompensated heart failure and the impact on prognosis. We also try to iden-
tify pathophysiological mechanisms, including which renal parameters best assess renal 
function in heart failure.
The pathophysiology of renal dysfunction in patients with heart failure is multifacto-
rial and associated with decreased perfusion, atherosclerosis, inflammation, endothelial 
dysfunction, and neurohormonal activation.8-10 Previous small studies in animals and hu-
mans suggested that central venous pressure might be associated with renal function.11-14
In addition to cardiac output, central venous pressure is an important hemodynamic 
factor in patients with heart failure. While decreased cardiac output occurs when the 
heart fails to pump enough blood to the organs, central venous pressure rises if the heart 
fails to handle the blood returning from the organs. This ‘backward failure’ leads to con-
gestion in systemic capillaries, leading to excess fluid accumulation in the body (edema). 
It is unclear whether central venous pressure may be related to renal function in a broad 
spectrum of patients cardiovascular disease.
In chapter 2, we assessed associations between renal dysfunction and hemodynamics 
in 2,557 patients who underwent right heart catheterization in the University Medical 
Center Groningen, the Netherlands, between 1989 and 2006.
We found that the two most important predictors of renal dysfunction are decreased 
cardiac output and increased central venous pressure. Central venous pressure was also a 
strong and independent determinant of all-cause mortality.
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To better understand the pathophysiological mechanisms connecting renal dysfunction 
and heart failure, it is important to determine which renal parameters best assess renal 
function in  patients with heart failure.
Renal function is usually measured by using serum creatinine to estimate glomerular 
filtration rate. Although estimated glomerular filtration rate is strongly associated with 
increased mortality in patients with heart failure, these findings are far less well-estab-
lished in the presence of mild renal impairment.6,15  Creatinine has limitations, such as 
relative insensitivity to small changes in actual glomerular filtration rate and dependency 
on muscle metabolism, weight, age and sex.
In addition to glomerular function, renal function also encompasses tubular function. 
In patients with intrinsic kidney failure, tubulointerstitial damage is an established marker 
for renal disease.16 Several studies showed that tubular markers are elevated before a risk 
in creatinine is observed.17-20 However, the prognostic value of plasma tubular damage 
markers in patients with normal or mildly impaired renal function is less well described.21
One of the tubular markers that can be measured in plasma is Neutrophil Gelatinase 
Associated Lipocalin (NGAL).
Chapter 3 assesses the role and performance of the tubular marker plasma NGAL as a 
prognostic marker for mortality in heart failure patients with both normal and impaired 
renal function. Secondy, the prognostic value of plasma NGAL is compared with creati-
nine and cystatin C, two frequently used biomarkers of chronic kidney disease.
In 562 patients with heart failure, NGAL predicted mortality, in patients with both pre-
served and impaired renal function. Moreover, plasma NGAL was a stronger predictor 
for mortality across the full range of renal function than the frequently used biomarkers 
such as creatinine. This may indicate that in heart failure patients, tubular damage may 
better reflect an impaired hemodynamic status than glomerular function.
As mentioned earlier, the complex reciprocal interaction between the heart and the kid-
neys is classified into 5 subtypes of the cardiorenal syndrome.7 In chapters 2 and 3, we 
have studied the prevalence, pathophysiologic mechanisms and prognostic implications 
of type 2 cardiorenal syndrome (chronic). In chapter 4, we focus on type 1 cardiorenal 
syndrome (acute) - acute abnormalities in cardiac function that result in acute kidney 
disease.
In acute heart failure, 20-40% of patients experience a rise in creatinine, which can be 
categorized into worsening renal function.13 Despite a high prevalence, many pathophysi-
ologic mechanisms remain unresolved. Previous studies showed worsening renal func-
tion may influence outcomes, although results are not consistent.15,22-24
In a retrospective analysis of a prospective randomized trial with a total of 7141 patients, 
we aimed to investigate the effects of nesiritide on renal function during hospitalization 
for acute decompensated heart failure. Of greater interest for this thesis, we also exam-
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ined the pathophysiologic associations and prognostic implications of (change in) creati-
nine. Baseline and discharge creatinine values were available in 4708 patients, allowing 
changes in renal function to be studied.
In this study, baseline renal function was mildly impaired and decreased further during 
hospitalization. Predictors of decline in renal function included higher systolic and lower 
diastolic blood pressure, lower potassium levels, more prior weight gain, and lower blood 
urea nitrogen levels, consistent with previous research.25,26
We conclude nesiritide did not affect renal function in patients with acute decompen-
sated heart failure, despite concerns raised by previous, smaller studies. Interestingly, we 
found both baseline and discharge renal function, but not worsening renal function or 
change in creatinine, were associated with 30-day mortality or re-hospitalization. 
There are several potential explanations for why change in creatinine was not associ-
ated with worse short-term outcome, in contrast to findings in other studies.15,22,23 For 
example, most studies do not measure creatinine routinely, so in those that did, there was 
probably a reason. The reason could be worsening symptoms, non-response to diuret-
ics, and an expectation of worse clinical outcomes.24 Supporting this hypothesis, a recent 
study in which serum creatinine levels were measured routinely, worsening renal func-
tion was not independently related to prognosis.24 Interestingly, that study found that 
worsening renal function was prognostic in patients with persistent signs of congestion, 
suggesting a differential effect of worsening renal function.  Additionally, the prospective, 
randomized DOSE-trial found that patients that were given high doses of diuretics had 
greater diuresis and more favorable outcomes, despite exhibiting more frequent transient 
worsening renal function.27 This suggests an increase in creatinine reflects decongestion 
due to response to diuretic therapy rather than true worsening of renal function in some 
patients.
Liver dysfunction
Liver function abnormalities, like renal dysfunction, are common in patients with heart 
failure. Although the presence of liver enzyme abnormalities in heart failure has long 
been recognized,28 the pathophysiologic mechanisms and the prognostic value of abnor-
mal liver function tests remain largely unknown. In chapters 2-4, we observed renal dys-
function was associated with both reduced cardiac output and increased central venous 
pressure. Individual small reports have highlighted the importance of high central ve-
nous pressure and reduced hepatic perfusion.29-31
In chapters 5 and 6, we assess prevalence of liver dysfunction in patients with chronic 
and acute decompensated heart failure and the impact on prognosis. We also try to eluci-
date pathophysiological mechanisms, focusing on hemodynamic factors such as cardiac 
output and central venous pressure.
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A few studies have highlighted the importance of either high central venous pressure 
or reduced hepatic dysfunction.29-31 However, the independent contribution of reduced 
cardiac output or increased central venous pressure in causing abnormalities in specific 
liver function tests has not been studied.
In chapter 5, we studied liver function in 323 patients with heart failure by determining 
aspartate and alanine aminotransferase (AST, ALT), alkaline phosphatase (ALKP), g-glu-
tamyl transpeptidase (GGT), lactate dehydrogenase (LDH) and direct and total bilirubin. 
Central venous pressure and cardiac output were determined invasively.
We show that abnormal liver enzymes are frequently found in patients with heart fail-
ure, with a prevalence of 30–60%, depending on the liver enzyme measured. Most ab-
normal liver enzymes show a relationship with increased venous congestion, while only 
some seem to be related to reduced cardiac output. Decreased cardiac output mainly cor-
relates with AST, ALT and bilirubin, while increased central venous pressure is associated 
with all liver enzyme tests, particularly GGT, ALKP and bilirubin. 
One reason low perfusion may be less important for liver function is the fact that oxy-
gen consumption can easily be increased even if hepatic blood flow is decreased, because 
only 30% of the liver’s blood supply is dependent on the hepatic artery.32 The remaining 
70% is provided by the portal system. 
In terms of prognosis, we found that levels of GGT, ALKP, AST and LDH were predic-
tors of all-cause mortality. Importantly, all liver function tests were non-significantly as-
sociated with all-cause mortality after correction for central venous pressure and cardiac 
output. Therefore, it is likely that the relationship between abnormal liver function tests 
and prognosis is merely a reflection of poor hemodynamic status.
Less is known about liver function in patients with acute decompensated heart fail-
ure33-35 while these patients are most likely to have impaired hemodynamics, making 
them vulnerable to impaired liver function. Previous reports have shown that the preva-
lence of abnormal liver function tests in acute decompensated heart failure is similar to 
chronic heart failure. In this hospitalized population, the interesting question is whether 
liver function test results change in response to therapy during re-hospitalization.
The prognostic value of impaired liver function tests in patients with acute heart failure 
is also less well established compared to chronic heart failure. Only one study assessed the 
in-hospital changes in liver function tests, and found albumin and bilirubin were associ-
ated with 180-day mortality in 2061 patients admitted with acute heart failure.33
In chapter 6, we investigated liver function tests at baseline and during hospitalization 
in 234 patients with acute decompensated heart failure. We examined the prognostic 
value of (change in) impaired liver function by assessing relationships with in-hospital 
worsening heart failure through day 5, 60-day mortality or re-hospitalization and 180-
day mortality.
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We found that abnormal liver function tests are prevalent in patients with acute de-
compensated heart failure - 20% of patients had abnormal AST and bilirubin, 10% had 
abnormal ALT and ALKP but almost no patients had abnormal levels of albumin and 
total protein. Liver function tests changed minimally during hospitalization, consistent 
with previously published data.33
As is also observed in chronic heart failure, abnormal liver function tests are common 
in acute heart failure patients and associated with an increased risk of mortality, re-hos-
pitalization and in-hospital worsening heart failure. However, changes in liver function 
tests were very small and not associated with prognosis.
Comorbidities
In chapter 7, we describe the prevalence of the most studied organ-related comorbidi-
ties in heart failure, i.e. renal dysfunction, cerebral and cognitive dysfunction, anaemia, 
liver dysfunction, chronic obstructive pulmonary disease, diabetes mellitus, depression, 
stroke and sleep apnea. We also provided potential explanations for the observed associa-
tion between comorbidities and heart failure, as well as effects on survival.
For the first time, we show the prevalence of comorbidities to be much higher in heart 
failure patients compared to an age-matched population. Although the pathophysiologic 
mechanisms are complex, remain largely unresolved and differ per comorbidity, we state 
multiple pathophysiologic factors are involved, including shared risk factors, inflamma-
tion, neurohumoral pathway activation and hemodynamic factors. The interactions be-
tween these factors make understanding the pathophysiology even more complex. 
Future perspective
This thesis has provided an overview of the prevalence, pathophysiology and prognosis 
of comorbidities in patients with heart failure. We have shown that comorbidities are fre-
quently observed in patients with acute and chronic heart failure, and that prevalence is 
higher compared to age-matched controls. Patients with more severe heart failure – high-
er NYHA class - had more comorbidities, confirming the hypothesis that heart failure 
causes comorbidities. We have shown that hemodynamic factors are an important patho-
physiologic link and that prognosis is worse when (multiple) comorbidities are present. 
However, many questions remain unanswered. For one, we must try to determine which 
heart failure patients develop which comorbidities. The complexity of the underlying 
network of pathophysiological mechanisms, with the potential for multiple interactions, 
complicates matters considerably. As a first step, comorbidities should be studied indi-
vidually, testing one hypothesis at a time. Given the marked regional differences, smaller, 
national studies may be preferable. However, it is likely certain factors have a role in not 
one, but multiple comorbidities. 
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In addition to studying individual comorbidities one hypothesis at a time, it is therefore 
essential that we collect as much data as we can. Developments in information technol-
ogy have helped advance knowledge by leaps and bounds – although the medical field has 
yet to fully grasp and deploy the potential benefits offered. Other industries have dem-
onstrated the major benefits of gathering large quantities of data. Such datasets require a 
different analytical approach to that commonly seen in the medical sciences – students 
t-test will need to make way for support vector machines and neural network computing.
Data storage efficiency should increase, as the information we currently ‘harvest’ is 
encoded in medical correspondence and images that are almost impossible to analyze. 
Rather than writing down or dictating a blood pressure measurement, time of measure-
ment, systolic and diastolic blood pressure measurements should be entered as unique 
entities, and allow the computer to generate the requisite sentence. This will free doctors 
to concentrate their attention on more important matters.
We should not limit data capture to variables seen by doctors, such as medical history, 
physical examination, medical conclusions, and so forth. Nurses collect data all day long 
as well, data crucial to better understanding the patient’s in-hospital journey. Machines 
also handle data which are not stored in analyzable entities; automatic storage of MRI, 
CT, echocardiographic and catheter instrument data in a single database could provide 
invaluable insights. In fact, implantable cardiac devices already store data for the manu-
facturers, data that could be helpful in the healthcare industry as well. Genetic material 
should also be included to allow genetic and epigenetic effects to be evaluated.
And one can only dream of what we could do if we could store and analyze all data that 
is generated by the patients themselves. Should we alert heart failure patients when they 
have twittered too many times that they have eaten ‘salted herring’? At the very least, we 
should look into variables that might explain which patients develop comorbidities and 
which patients do not. Because the answer to this complex pathophysiological web of rid-
dles will not be found inside the hospital walls alone.
In conclusion, comorbidities frequently accompany heart failure and worsen morbidity 
and mortality. Although heart failure has a potential causal relation, the complex patho-
physiological mechanisms remain unresolved.
Comorbidities could be studied separately, but it is likely certain factors have a role in 
not one, but in multiple comorbidities. Therefore, comorbidities must be studied simul-
taneously as well. In 1894, William Osler stated that in order “to know fully many of the 
most important diseases a man must be familiar with their manifestations in many or-
gans” (William Osler, The army Surgeon, Medical News, Philidelphia, 1894).
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Hartfalen is een klinisch syndroom waarbij het hart niet in staat is om het lichaam van 
zijn behoefte te voorzien. Het gaat gepaard met het vasthouden van vocht, kortademig-
heid en verminderde inspanningstolerantie.1 Patiënten met hartfalen hebben een slechte 
kwaliteit van leven en een verhoogde kans op ziekenhuisopname en sterfte.2 Er komt 
steeds meer bewijs dat patiënten met hartfalen andere ziekten hebben. Deze ‘comorbid-
iteiten’ komen vaak voor bij hartfalen en verslechteren de kwaliteit van leven en verhogen 
de sterftekans.
Doelen
Dit proefschrift heeft als doel om te achterhalen:
1. wat de prevalentie is van individuele en gezamenlijke comorbiditeiten bij hartfalen;
2. of de prevalentie van comorbiditeiten hoger is bij hartfalen dan bij leeftijdsgenoten;
3. wat de mechanismen zijn tussen hartfalen en verschillende comorbiditeiten, eve-
nals de factoren die geassocieerd zijn met meerdere comorbiditeiten;
4. wat de prognostische betekenis is van individuele en meerdere comorbiditeiten.
Comorbiditeiten
Hoewel talrijke studies zich op een afzonderlijke comorbiditeit hebben gericht, zijn er 
weinig studies die zich richten op meerdere niet-cardiale comorbiditeiten bij patiënten 
met hartfalen.3,4 Tot nu toe is onbekend welke factoren zorgen voor meerdere comorbid-
iteiten bij patiënten met hartfalen.
Hoofdstuk 1 onderzocht meerdere comorbiditeiten in 3226 Europese patiënten met 
chronisch hartfalen. We hebben ons gericht op de prevalentie, determinanten, regionale 
variatie en prognostische implicaties van comorbiditeiten.
We concludeerden dat de meerderheid van de patiënten ten minste één comorbiditeit 
had en dat het aantal comorbiditeiten toenam met de ernst van hartfalen. De comorbid-
iteiten diabetes, chronische nierziekte en anemie waren onafhankelijk geassocieerd met 
een verhoogd risico op ziekenhuisopname en sterfte. Interessant om te vermelden is dat 
er duidelijke verschillen waren in verschillende regio’s van Europa.
In de volgende hoofdstukken hebben we gekeken naar de comorbiditeiten die direct 
gerelateerd zijn aan een orgaan - nierfunctiestoornissen en leverfunctiestoornissen. Hier-
door zijn ze relatief eenvoudig te bestuderen op een continue schaal. Dit maakt het mak-




Een van de belangrijkste comorbiditeiten bij hartfalen is nierinsufficiëntie.5-7 We weten 
dat hartfalen nierfunctiestoornissen kan veroorzaken, en andersom kunnen nierfunc-
tiestoornissen ook hartfalen veroorzaken. Beide worden veroorzaakt door gemeenschap-
pelijke risicofactoren zoals een hoge bloeddruk, diabetes en onderliggend atherosclerose. 
In de hoofdstukken 2-4 onderzochten we zowel de prevalentie van nierfunctiestoornis-
sen bij patiënten met chronisch en acuut hartfalen als de invloed op de prognose. We 
probeerden ook om enkele mechanismen te identificeren.
De mechanismen tussen nierfunctiestoornissen en hartfalen zijn veelzijdig en complex. 
Verminderde perfusie, atherosclerose, inflammatie, endotheel disfunctie en neurohor-
monale activatie zijn enkele factoren die meespelen.8-10 Ook zou een verhoogde centraal 
veneuze druk een rol kunnen spelen.11-14
De centraal veneuze druk is naast het hartminuutvolume een belangrijke hemodyna-
mische factor bij patiënten met hartfalen. Het hartminuutvolume is bij deze patiënten 
verminderd omdat het hart niet in staat is om voldoende bloed rond te pompen naar de 
organen. De centraal veneuze druk stijgt wanneer het hart niet in staat is om het bloed 
vanuit de organen weg te pompen. Dit leidt uiteindelijk tot ophoping van overtollig vocht 
in het lichaam (oedeem).
In hoofdstuk 2 bevestigden we de associaties tussen nierfunctiestoornissen en hemo-
dynamiek bij 2557 patiënten met hartfalen. We vonden dat een verminderde hartmin-
uutvolume en een verhoogde centrale veneuze druk de twee belangrijkste voorspellers 
waren van nierfunctiestoornissen. Een verhoogde centraal veneuze druk was daarnaast 
een onafhankelijke voorspeller voor overlijden.
Om een beter inzicht te krijgen in de mechanismen tussen hartfalen en nierfunc-
tiestoornissen hebben we gekeken naar verschillende markers voor de nierfunctie. Hoe-
wel de glomerulaire marker kreatinine meestal wordt gebruikt, heeft kreatinine ook 
een aantal tekortkomingen.6,15 Zo wordt kreatinine beïnvloed door factoren als leeftijd, 
geslacht, spiermetabolisme en gewicht en is kreatinine relatief ongevoelig voor kleine 
wijzigingen in de nierfunctie. 
In hoofdstuk 3 hebben we onder andere gekeken naar NGAL (Neutrofiel Gelatinase 
Geassocieerd Lipocaline). Dit is een schademarker van het tubulaire deel van de nier en 
is verhoogd bij patiënten met hartfalen.16-21 In 562 patiënten met hartfalen zagen we dat 
NGAL een sterkere voorspeller is voor sterfte dan kreatinine. We zagen zelfs dat NGAL 
was verhoogd bij normale waarden van kreatinine. Dit kan erop wijzen dat tubulaire nier-
schade de verslechterde hemodynamische status beter weerspiegelt dan de glomerulaire 
functie bij patiënten met hartfalen.
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Naast chronisch hartfalen hebben we ook gekeken naar acuut hartfalen. Van de patiënt-
en die worden opgenomen met acuut hartfalen weten we dat de nierfunctie in 20-40% 
nog verder achteruit gaat.13 Het is echter nog onduidelijk welke mechanisme meespelen. 
Ook weten we niet zeker of een verslechtering van de nierfunctie zorgt voor een hogere 
sterfte.15,22-24
In hoofdstuk 4 hebben we in 7141 patiënten met acuut hartfalen gekeken naar de ef-
fecten van het medicijn nesiritide op de nierfunctie. Voor dit proefschrift is het van be-
lang dat we ook keken naar de verandering van de nierfunctie, gemeten met kreatinine.
Voorspellers van een verslechtering van de nierfunctie waren een hogere systolische 
bloeddruk, een lagere diastolische bloeddruk, gewichtstoename vóór opname, een lager 
kalium en een lager ureum.25,26
We concludeerden dat een slechte nierfunctie geassocieerd is met een hogere sterfte, 
maar dat verdere verslechtering van de nierfunctie niet geassocieerd is met ziekenhuiso-
pnames of sterfte binnen dertig dagen.
Een mogelijke verklaring is dat een toename van kreatinine in sommige patiënten niet 
betekent dat de nierfunctie is afgenomen, maar dat de medicijnen voor hartfalen goed 
werken.27 Deze patiëntengroep krijgt namelijk vaak een diureticum dat bij een positief 
effect het kreatinine kan verhogen.
Leverfunctiestoornissen
Leverfunctiestoornissen komen vaak voor bij patiënten met hartfalen. Hoewel dit al 
langer bekend is, blijven de mechanismen en de prognostische waarde van afwijkende 
leverfuncties grotendeels een raadsel.28
Net als bij nierfunctiestoornissen laten kleine studies het mogelijke belang zien van een 
hoge centraal veneuze druk en verminderde leverperfusie.29-31 Echter, de onafhankelijke 
bijdrage van een verminderd hartminuutvolume en verhoogde centraal veneuze druk op 
de leverfunctie is niet onderzocht.
In de hoofdstukken 5 en 6 onderzochten we de prevalentie van leverfunctiestoornis-
sen bij patiënten met chronisch én acuut hartfalen alsmede de invloed op prognose. We 
keken ook naar mogelijke mechanismen, met name de hemodynamische factoren zoals 
hartminuutvolume en centrale veneuze druk.
In hoofdstuk 5 onderzochten we de leverfunctie bij 323 patiënten met chronisch hart-
falen door het bepalen van verschillende leverfunctietesten. We zagen dat 30-60% van de 
patiënten een afwijkende leverfunctie had, afhankelijk van welke leverfunctietest werd 
gemeten. 
De meeste abnormale leverfunctietesten waren geassocieerd met een verhoogde cen-
traal veneuze druk, terwijl slechts enkele geassocieerd waren met een verminderd hart-
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minuutvolume. Een mogelijke verklaring waarom een lage perfusie minder belangrijk is 
voor de leverfunctie, is dat de lever in gezonde toestand meer bloed krijgt dan nodig is. In 
meer detail, slechts 30% van bloedtoevoer van de lever is afhankelijk van de leverslagader, 
terwijl de resterende 70% vanuit het portaal systeem komt.32
Verder vonden we dat een aantal leverfunctietesten geassocieerd waren met een ver-
hoogde sterftekans. Belangrijker is dat deze relatie verdween als we corrigeerden voor het 
hartminuutvolume en de centraal veneuze druk. Waarschijnlijk is de relatie tussen afwi-
jkende leverfunctietesten en verhoogde sterftekans enkel een afspiegeling van de hemo-
dynamische toestand van de patiënt.
Naast chronisch hartfalen hebben we de leverfunctie ook bekeken bij patiënten met 
acuut hartfalen. Over de leverfunctie in patiënten die opgenomen worden met acuut 
hartfalen is minder bekend.33-35 Deze patiëntengroep is interessant omdat de hemody-
namiek bij deze patiënten verstoord is waardoor de leverfunctie mogelijk kwetsbaar is. 
We hebben ook gekeken naar de verandering van de leverfunctie tijdens de opname en of 
dit invloed had op de sterfte. 
In hoofdstuk 6 hebben we 234 patiënten onderzocht die werden opgenomen met acuut 
hartfalen. Zowel bij binnenkomst als tijdens de ziekenhuisopname waren de leverfuncti-
etesten gemeten. We hebben naar meerdere eindpunten gekeken, waaronder verergering 
van hartfalen tijdens de ziekenhuisopname, sterfte of heropname binnen 60 dagen, en 
naar sterfte binnen 180 dagen. 
We zagen dat de meeste leverfunctietesten afwijkend waren met een prevalentie van 10-
20%. De leverfunctietesten veranderden echter minimaal tijdens de ziekenhuisopname, 
wat consistent is met een eerder gepubliceerd onderzoek.33 Net als bij chronisch hartfalen 
zagen we dat de meeste leverfunctietesten geassocieerd waren met verhoogde sterfte en 
heropname. Echter, verandering van de leverfunctietesten tijdens opname waren klein en 
niet geassocieerd met sterfte en heropname.
Comorbiditeit
In hoofdstuk 7 beschreven we de prevalentie van de meest bestudeerde orgaan-ger-
elateerde comorbiditeiten in hartfalen - nierinsufficiëntie, cerebrale en cognitieve dys-
functie, anemie, lever disfunctie, chronische obstructieve longziekte, diabetes mellitus, 
depressie, beroerte en slaapapneu. Tevens beschreven we mogelijke verklaringen voor de 
waargenomen associatie tussen deze comorbiditeiten en hartfalen, evenals de nadelige 
effecten op de overleving.
Voor de eerste keer lieten we zien dat de prevalentie van comorbiditeiten in patiënten 
met hartfalen hoger is in vergelijking met leeftijdsgenoten. We zagen dat meerdere mech-
anismen hierbij betrokken waren - gedeelde risicofactoren, ontsteking, neurohormonale 
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activatie en ook hemodynamische factoren. Echter, de mechanismen verschillen per co-
morbiditeit en zijn nog  grotendeels onopgelost. 
Toekomstperspectief
Dit proefschrift geeft een overzicht van de prevalentie, mechanismen en prognose van 
comorbiditeiten bij patiënten met hartfalen. We hebben aangetoond dat comorbiditeiten 
vaak voorkomen bij patiënten met acuut en chronisch hartfalen, en dat de prevalentie 
hoger is in vergelijking met leeftijdsgenoten. De observatie dat patiënten met ernstiger 
hartfalen vaker comorbiditeiten hebben is in lijn met de hypothese dat comorbiditeiten 
veroorzaakt kunnen worden door hartfalen, waarbij hemodynamische factoren een rol 
lijken te spelen. Tevens hebben we aangetoond dat de prognose slechter is wanneer een 
patiënt meerdere comorbiditeiten heeft.
Er blijven echter veel vragen onbeantwoord. Zo moeten we er onder andere proberen 
achter te komen welke patiënten met hartfalen comorbiditeiten ontwikkelen. Hiervoor 
zullen we elke comorbiditeit individueel moeten bestuderen, waarbij we elke hypothese 
één voor één bij langs gaan. 
Het is echter waarschijnlijk dat sommige factoren een rol spelen in meerdere comorbid-
iteiten tegelijk met meerdere interacties onderling. Naast het bestuderen van individuele 
comorbiditeiten is een tweede aanpak daarom essentieel; zoveel mogelijk gegevens ver-
zamelen. Hiervoor moeten we gebruik maken van de informatietechnologie, die zich de 
afgelopen jaren sterk heeft ontwikkeld. Andere sectoren hebben reeds aangetoond dat 
er grote voordelen zitten aan het verzamelen van grote hoeveelheden data. Helaas is de 
medische sector achtergebleven met het benutten van deze voordelen. 
Dergelijke grote datasets vereisen ook een andere analytische aanpak dan de medische 
sector tot nu toe gewend is – de simpele t-test zal plaats moeten maken voor support vec-
tor machines en neural network computing.
Ook de manier waarop data wordt opgeslagen zal moeten veranderen. De informatie 
die we op dit moment ‘oogsten’ is gecodeerd in brieven en beelden die bijna onmogelijk 
te analyseren zijn. Daarom moet we data niet dicteren in brieven maar per variabele 
opslaan – bij een bloeddrukmeting moet bijvoorbeeld automatisch de tijd van de met-
ing, de systolische bloeddruk en diastolische bloeddruk worden opgeslagen. Nadat deze 
unieke entiteiten zijn ingevoerd, kan de computer automatisch de vereiste zin in een brief 
genereren. Een extra voordeel is dat artsen hierdoor tijd besparen die ze kunnen gebruik-
en om zich op belangrijkere zaken te concentreren.
We moeten ons overigens niet beperken tot de gegevens die artsen genereren, zoals 
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medische anamnese, lichamelijk onderzoek, medische conclusies, enzovoort. Verpleeg-
kundigen verzamelen namelijk ook gegevens. Deze data is cruciaal voor een beter begrip 
van de reis die de patiënt in het ziekenhuis aflegt. Ook machines verwerken gegevens die 
nu niet worden opgeslagen in analyseerbare entiteiten. We zouden moeten overgaan op 
automatische opslag van data afkomstig van MRI, CT, echocardiografie en zelfs kathe-
ter-instrumenten. Ook genetisch materiaal kunnen we aan zo’n dataset toevoegen. Deze 
grote datastromen bevatten waardevolle informatie die wij in de medische wetenschap 
nog niet benutten. Informatie die implanteerbare cardiale apparaten genereren wordt nu 
alleen opgeslagen door de fabrikanten. 
Men kan alleen maar dromen over wat we zouden kunnen doen met de data die wordt 
gegenereerd door de patiënt zelf. Denk bijvoorbeeld aan twitter. Als we deze data kun-
nen opslaan en analyseren komen we er mogelijk achter waarom sommige patiënten wel 
worden opgenomen en anderen niet. Sturen we patiënten met hartfalen in de toekomst 
een sms als ze te vaak ‘zoute haring’ twitteren? Dit is nu nog moeilijk voor te stellen, maar 
we weten al wel dat er talloze vragen in de gezondheidszorg zijn waarvan we het ant-
woord niet binnen de muren van het ziekenhuis gaan vinden. Zo ook de vraag waarom 
sommige patiënten comorbiditeiten ontwikkelen en anderen patiënten niet. 
Concluderend, comorbiditeiten komen vaak voor bij patiënten met hartfalen en ver-
hogen de ziektelast en de sterftekans. Hoewel hartfalen mogelijk een rol speelt bij het 
ontstaan van comorbiditeiten blijven de complexe mechanismen onopgelost. We moe-
ten comorbiditeiten en mogelijke mechanismen zowel afzonderlijk onderzoeken als ook 
tegelijkertijd. In 1894 werd al gezegd dat een man een ziekte pas compleet begrijpt wan-
neer hij weet welke gevolgen deze ziekte heeft in andere organen (William Osler, The 
army Surgeon, Medical News, Philidelphia, 1894).
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159Statements
De verstoorde hemodynamiek bij hartfalen zorgt voor het ontstaan van comor-
biditeiten. (dit proefschrift)
Leverfunctiestoornissen bij hartfalen zijn een reflectie van de ernst van het hart-
falen. (dit proefschrift)
Kreatinine is een overschatte marker voor het bepalen van de nierfunctie bij hart-
falen. (dit proefschrift)
Verslechtering van de nierfunctie bij hartfalen kan een gunstig teken zijn. (dit 
proefschrift)
In de praktijk worden comorbiditeiten bij hartfalen vaak gemist; Dit is vooral het 
geval bij slaapapneu. (dit proefschrift)
De manier van het doen van onderzoek moet in de toekomst veranderen door 




Elke stelling is waar of niet waar. Er is geen tussenweg.
Mensen die zeggen dat je niet alles zwart-wit moet zien snappen niet dat grijze 
gebieden veroorzaakt worden door een slechte differentiatie.
Als iedereen aan zichzelf denkt wordt niemand vergeten.
Een plan hebben is goed maar een planning maken is slecht. Dit komt omdat de 
tweede stap afhankelijk is van de uitkomst van de eerste.
Iedereen weet dat 2,5 plus 3,5 gelijk is aan 6. Dus als je 3,5 afrondt naar 4, moet je 
2,5 afronden naar 2.
Wanneer een groep (of persoon) fouten stigmatiseert, verdrijven ze creativiteit en 
daarmee innovatie.
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